A frequency trend analysis of major and critical audit finding groupings for clinical trials involving central nervous system studies by Louw, Elma
A FREQUENCY TREND ANALYSIS OF MAJOR AND CRITICAL AUDIT 
FINDING GROUPINGS FOR CLINICAL TRIALS INVOLVING CENTRAL 
NERVOUS SYSTEM STUDIES 
 
Elma Louw 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A research report submitted to the Faculty of Health Sciences, University of the 
Witwatersrand, Johannesburg, in partial fulfillment of the requirements for the degree of 
Masters of Science in Medicine in Pharmaceutical Affairs 
 
Pretoria, 2008 
  i
DECLARATION 
I, Elma Louw, declare that this research report is my own work. It is being submitted for 
the degree of Masters of Science in Medicine in the branch of Pharmaceutical Affairs in 
the University of the Witwatersrand, Johannesburg. It has not been submitted before for 
any degree or examination at this or any other University. 
 
_________________________ 
 
 
_________ day of _________________________, _______________ 
  ii
DEDICATION 
 
To my husband 
Thank you for all the support and for making life so much easier when I paid so much 
attention to the computer. 
 
  iii
ABSTRACT 
 
Quality Assurance (QA) Audits are an essential component and an integral part of 
clinical trials. As a quality improvement tool, forming part of Good Clinical Practice 
(GCP) an audit can demonstrate that real efforts are being made to improve and enhance 
the quality of professional care to all trial subjects participating in clinical trials. 
Specifically, clinical research performed on the central nervous system (CNS) involves 
distinctive areas of concern to adherence to good clinical practice in this therapeutic area. 
For example an informed consent process not conducted appropriately for subjects with 
e.g. Schizophrenia or Alzheimer’s disease; or inter-individual rating differences in 
instances when different investigators (psychiatrist) assess a trial subject. A need was 
identified to analyze the association between the CNS indication audited and the audit 
findings and to perform a trend analysis that highlight re-occuring audit findings.  
 
A total of 123 CNS audit reports were obtained from the Quality Assurance Departments 
of Quintiles in South Africa and Europe. The audit reports were grouped into the 15 CNS 
indications that were audited.  Five hundred and six (506) audit findings were derived 
from the 123 CNS audits reports. The audit findings were categorized according to GCP 
subject matter, regulatory requirements or Standard Operating Procedures (SOPs).  The 
severity of audit findings was classified as critical or major.  
 
The results of this investigation suggested a need for substantial improvement in three 
important areas. Firstly; adherence to the study requirements inclusive of relevant 
Standard Operating Procedures (SOPs). Secondly the development of better defined 
protocols and thirdly training of monitors. Study planners and Clinical Trial Management 
should take a proactive role to minimize the audit findings by ensuring monitors with 
experience in the research field should be involved in the study. Procedures should be 
implemented to educate site staff. Focus should be placed on the importance of detailed 
source documentation, adherence to investigational product dosage requirements, the 
conduct of the informed consent process, and adequate study documentation 
maintenance.  
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NOMENCLATURE: LIST OF ABBREVIATIONS  
 
CNS  Central Nervous System  
CRF  Case Record Form  
CRO  Clinical Research Organization  
CSV  Computer System Validation  
CV  Curriculum vitae  
FDA, CFR USA Code of Federal Regulations  
GAD  Generalized Anxiety Disorder  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice Guideline  
ICH GCP  International Conference of Harmonization Good Clinical Practice  
IEC  Independent Ethics Committee  
IP  Investigational Product  
IRB  Institutional Review Board  
ISF Investigator Site File  
MCC  Medicine Control Council  
MDD  Major Depressive Disorder  
OHRP  Office of Human Research Protection  
PHND  Post Herpgic Neuralgia Disorder  
PI  Principal Investigator  
QA   Quality Assurance  
SAE  Serious Adverse Events  
SAGCP Conduct of Clinical Trials in Human Participants in South African 
SDV  Source Data Verification  
SOP  Standard Operating Procedures  
TMF  Trial Master File  
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NOMENCLATURE: GLOSSARY 
    
Adverse Drug Reaction (ADR)    
In the pre-approval clinical experience with a new medicinal product or its new usages, 
particularly as the therapeutic dose(s) may not be established: all noxious and unintended 
responses to a medicinal product related to any dose should be considered adverse drug 
reactions. The phrase responses to a medicinal product means that a causal relationship 
between a medicinal product and an adverse event is at least a reasonable possibility, i.e. 
the relationship cannot be ruled out. 
Regarding marketed medicinal products: a response to a drug which is noxious and 
unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or 
therapy of diseases or for modification of physiological function. 
 
Adverse Event (AE) 
Any untoward medical occurrence in a patient, or clinical investigation subject, 
administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment. An adverse event (AE) can therefore be any unfavorable 
and unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or not 
related to the medicinal (investigational) product. 
 
Applicable Regulatory Requirement(s) 
Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational 
products. 
 
Approval (in relation to Institutional Review Boards) 
The affirmative decision of the IRB that the clinical trial has been reviewed and may be 
conducted at the institution site within the constraints set forth by the IRB, the institution, 
Good Clinical Practice (GCP), and the applicable regulatory requirements. 
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Audit  
A systematic and independent examination of trial related activities and documents to 
determine whether the evaluated trial related activities were conducted, and the data were 
recorded, analyzed and accurately reported according to the protocol, sponsor's standard 
operating procedures (SOPs), Good Clinical Practice (GCP), and the applicable regulatory 
requirement(s). 
 
Audit Certificate 
A declaration of confirmation by the auditor that an audit has taken place. 
 
Audit Report 
A written evaluation by the sponsor's auditor of the results of the audit. 
 
Audit Trail 
Documentation that allows reconstruction of the course of events. 
 
Case Record Form (CRF) 
A printed, optical, or electronic document designed to record all of the protocol required 
information to be reported to the sponsor on each trial subject. 
 
Clinical Trial/Study 
Any investigation in human subjects intended to discover or verify the clinical, 
pharmacological and/or other pharmacodynamic effects of an investigational product(s), 
and/or to identify any adverse reactions to an investigational product(s), and/or to study 
absorption, distribution, metabolism, and excretion of an investigational product(s) with 
the object of ascertaining its safety and/or efficacy. The terms clinical trial and clinical 
study are synonymous. 
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Comparator (Product) 
An investigational or marketed product (i.e., active control), or placebo, used as a 
reference in a clinical trial. 
 
Compliance (in relation to trials) 
Adherence to all the trial-related requirements, Good Clinical Practice (GCP) 
requirements, and the applicable regulatory requirements. 
 
Confidentiality 
Prevention of disclosure, to other than authorized individuals, of a sponsor's proprietary 
information or of a subject's identity. 
 
Contract 
A written, dated, and signed agreement between two or more involved parties that sets out 
any arrangements on delegation and distribution of tasks and obligations and, if 
appropriate, on financial matters. The protocol may serve as the basis of a contract. 
 
Contract Research Organization (CRO) 
A person or an organization (commercial, academic, or other) contracted by the sponsor to 
perform one or more of a sponsor's trial-related duties and functions. 
 
Direct Access 
Permission to examine, analyzes, verify, and reproduce any records and reports that are 
important to evaluation of a clinical trial. Any party (e.g., domestic and foreign regulatory 
authorities, sponsor's monitors and auditors) with direct access should take all reasonable 
precautions within the constraints of the applicable regulatory requirement(s) to maintain 
the confidentiality of subjects' identities and sponsor’s proprietary information. 
 
 
 
                                   
 xiii  
Documentation 
All records, in any form (including, but not limited to, written, electronic, magnetic, and 
optical records, and scans, x-rays, and electrocardiograms) that describe or record the 
methods, conduct, and/or results of a trial, the factors affecting a trial, and the actions 
taken. 
 
Essential Documents 
Documents which individually and collectively permit evaluation of the conduct of a 
study and the quality of the data produced. 
 
Good Clinical Practice (GCP) 
A standard for the design, conduct, performance, monitoring, auditing, recording, 
analyses, and reporting of clinical trials that provides assurance that the data and reported 
results are credible and accurate, and that the rights, integrity, and confidentiality of trial 
subjects are protected. 
 
Impartial Witness 
A person, who is independent of the trial, who cannot be unfairly influenced by people 
involved with the trial, who attends the informed consent process if the subject or the 
subject’s legally acceptable representative cannot read, and who reads the informed 
consent form and any other written information supplied to the subject. 
 
Independent Ethics Committee (IEC) 
An independent body (a review board or a committee, institutional, regional, national, or 
supranational), constituted of medical/scientific professionals and non-medical/non-
scientific members, whose responsibility it is to ensure the protection of the rights, safety 
and well-being of human subjects involved in a trial and to provide public assurance of 
that protection, by, among other things, reviewing and approving / providing favorable 
opinion on, the trial protocol, the suitability of the investigator(s), facilities, and the 
methods and material to be used in obtaining and documenting informed consent of the 
trial subjects. 
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The legal status, composition, function, operations and regulatory requirements pertaining 
to Independent Ethics Committees may differ among countries, but should allow the 
Independent Ethics Committee to act in agreement with GCP as described in this 
guideline. 
 
Informed Consent 
A process by which a subject voluntarily confirms his or her willingness to participate in a 
particular trial, after having been informed of all aspects of the trial that are relevant to the 
subject's decision to participate. Informed consent is documented by means of a written, 
signed and dated informed consent form. 
 
Inspection 
The act by a regulatory authority(ies) of conducting an official review of documents, 
facilities, records, and any other resources that are deemed by the authority(ies) to be 
related to the clinical trial and that may be located at the site of the trial, at the sponsor's 
and/or contract research organization’s (CRO’s) facilities, or at other establishments 
deemed appropriate by the regulatory authority(ies). 
 
Institution (medical)  
Any public or private entity or agency or medical or dental facility where clinical trials are 
conducted. 
 
Institutional Review Board (IRB) 
An independent body constituted of medical, scientific, and non-scientific members, 
whose responsibility is to ensure the protection of the rights, safety and well-being of 
human subjects involved in a trial by, among other things, reviewing, approving, and 
providing continuing review of trial protocol and amendments and of the methods and 
material to be used in obtaining and documenting informed consent of the trial subjects. 
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Investigational Product 
A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including a product with a marketing authorization when used 
or assembled (formulated or packaged) in a way different from the approved form, or 
when used for an unapproved indication, or when used to gain further information about 
an approved use. 
 
Investigator 
A person responsible for the conduct of the clinical trial at a trial site. If a trial is 
conducted by a team of individuals at a trial site, the investigator is the responsible leader 
of the team and may be called the principal investigator. See also Sub investigator.  
 
Investigator / Institution 
An expression meaning "the investigator and/or institution, where required by the 
applicable regulatory requirements". 
 
Investigator's Brochure 
A compilation of the clinical and nonclinical data on the investigational product(s) which 
is relevant to the study of the investigational product(s) in human subjects.  
 
Legally Acceptable Representative 
An individual or juridical or other body authorized under applicable law to consent, on 
behalf of a prospective subject, to the subject's participation in the clinical trial. 
 
Monitoring 
The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, 
recorded, and reported in accordance with the protocol, Standard Operating Procedures 
(SOPs), Good Clinical Practice (GCP), and the applicable regulatory requirement(s).  
 
 
                                   
 xvi  
Monitoring Report 
A written report from the monitor to the sponsor after each site visit and/or other trial-
related communication according to the sponsor’s SOPs. 
 
Opinion (in relation to Independent Ethics Committee) 
The judgment and/or the advice provided by an Independent Ethics Committee (IEC).  
 
Original Medical Record 
See Source Documents. 
 
Protocol 
A document that describes the objective(s), design, methodology, statistical 
considerations, and organization of a trial. The protocol usually also gives the background 
and rationale for the trial, but these could be provided in other protocol referenced 
documents. 
 
Protocol Amendment 
A written description of a change(s) to or formal clarification of a protocol. 
 
Quality Assurance (QA) 
All those planned and systematic actions that are established to ensure that the trial is 
performed and the data are generated, documented (recorded), and reported in compliance 
with Good Clinical Practice (GCP) and the applicable regulatory requirement(s).  
 
Quality Control (QC) 
The operational techniques and activities undertaken within the quality assurance system 
to verify that the requirements for quality of the trial-related activities have been fulfilled. 
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Regulatory Authorities  
Bodies having the power to regulate. In the ICH GCP guideline the expression Regulatory 
Authorities includes the authorities that review submitted clinical data and those that 
conduct inspections. These bodies are sometimes referred to as competent authorities. 
 
Serious Adverse Event (SAE) or Serious Adverse Drug Reaction (Serious ADR) 
Any untoward medical occurrence that at any dose: 
results in death, is life-threatening, requires inpatient hospitalization or prolongation of 
existing hospitalization, results in persistent or significant disability/incapacity, or 
is a congenital anomaly/birth defect  
 
Source Data 
All information in original records and certified copies of original records of clinical 
findings, observations, or other activities in a clinical trial necessary for the reconstruction 
and evaluation of the trial. Source data are contained in source documents (original 
records or certified copies). 
 
Source Documents 
Original documents, data, and records (e.g., hospital records, clinical and office charts, 
laboratory notes, memoranda, subjects' diaries or evaluation checklists, pharmacy 
dispensing records, recorded data from automated instruments, copies or transcriptions 
certified after verification as being accurate copies, microfiches, photographic negatives, 
microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at 
the laboratories and at medico-technical departments involved in the clinical trial). 
 
Sponsor 
An individual, company, institution, or organization which takes responsibility for the 
initiation, management, and/or financing of a clinical trial. 
 
 
                                   
 xviii  
Standard Operating Procedures (SOPs) 
Detailed, written instructions to achieve uniformity of the performance of a specific 
function. 
 
Sub investigator 
Any individual member of the clinical trial team designated and supervised by the 
investigator at a trial site to perform critical trial-related procedures and/or to make 
important trial-related decisions (e.g., associates, residents, research fellows). See also 
Investigator. 
 
Subject/Trial Subject 
An individual who participates in a clinical trial, either as a recipient of the investigational 
product(s) or as a control. 
 
Trial Site 
The location(s) where trial-related activities are actually conducted. 
 
Vulnerable Subjects 
Individuals whose willingness to volunteer in a clinical trial may be unduly influenced by 
the expectation, whether justified or not, of benefits associated with participation, or of a 
retaliatory response from senior members of a hierarchy in case of refusal to participate. 
Examples are members of a group with a hierarchical structure, such as medical, 
pharmacy, dental, and nursing students, subordinate hospital and laboratory personnel, 
employees of the pharmaceutical industry, members of the armed forces, and persons kept 
in detention. Other vulnerable subjects include patients with incurable diseases, persons in 
nursing homes, unemployed or impoverished persons, and patients in emergency 
situations, ethnic minority groups, homeless persons, nomads, refugees, minors, and those 
incapable of giving consent. 
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CHAPTER 1 
1.0 INTRODUCTION 
1.1 What is a Clinical Trial? 
 
A clinical trial is a drug study often, but not always sponsored by a pharmaceutical or 
biotechnology company. Health-related government agencies could also provide funding 
for a clinical trial. The purpose of these studies is to find out whether a medication is safe 
to use and effective against various diseases, indications or medical conditions. In order to 
study the medication, several questions need to be clarified. For example, what patient 
population or disease is the drug meant to treat?. What criteria should be used for 
accepting participants into the study?. What general and disease-specific information are 
the study doctors going to obtain?(1).  
 
1.2 The role of Quality Assurance in Clinical Trials 
 
Societies are increasingly questioning quality of care and concepts of professional 
discretion or clinical freedom in the conduct of clinical trials. The stark evidence of this 
shift in attitudes towards clinical trials is shown in the demands of pressure groups, press 
coverage, calls for public inquiries, and the increase of complaints, legal challenges and 
claims for redress(2). 
 
Investigators, trial participants, sponsors, clinical research organizations (CROs), ethics 
committees and the wider public all share equally in the need to establish and maintain 
confidence in the quality of clinical trials performed on human participants. Quality 
assurance auditing is one of the most important aspects of clinical research that can serve 
and be used to retain the trust and respect in an increasingly critical environment (1). 
 
Audit is not a new process. As early as 1750 BC, King Hammurabi of Babylon instigated 
audit for clinicians with regard to outcome, sometimes with serious consequences for the 
clinician both financially, and with regard to life and limb, in the event of poor 
performance(3). 
Clinical audit has moved on from these early beginnings, but it was only between 1989 
and 1990, that money was first made available to finance the development of audit 
activity in clinical trials (3).  
                                   
 2  
QA audits are performed to assure and to demonstrate that clinical trials are organized and 
conducted in compliance with the Guidelines for Good Practice in the Conduct of Clinical 
Trials in Human Participants in South African (SAGCP), local regulatory requirements 
(Medicines Control Council (MCC)), The USA Code of Federal Regulations (FDA; 
21CFR parts 50, 54, 56 and 312),  OHRP –Office of Human Research Protection, 
International Conference of Harmonization Good Clinical Practice (ICH GCP), Good 
Laboratory Practice Guideline (GLP), company policies (either Pharmaceutical or Clinical 
Research Organization (CRO)) in addition to the written commitments to the sponsor. 
Thus, it provides additional confidence to the sponsor concerning the validity and 
accuracy of clinical study data (4). 
 
1.3 Type of Audit 
 
Different types of clinical trial audits could be performed, depending on the reason for the 
audit, the scope of the audit and/or the objective of the audit. For example Trial Master 
File Audit, Data Management Audit, System Audit and Investigational Site Audit, 
Laboratory Audits and Drug Manufacturing Audits. For the purpose of this research report 
the conduct of Trial Master File and Investigator Site Audits are explained in section 1.3.1 
and 1.3.2 of this report.  
 
There is no established guideline, which determines the number, type and frequency of an 
audit that should be conducted per study. The decision should be guided by the quality 
concerns raised by study team; 
• Importance of a study:– major contribution to data, geographical spread,  
• New or previously un-audited investigator;  
• Significant findings noted during previous audits;  
• Data anomalies - e.g. multiple protocol violations;  
• Unexpected high incidence of serious adverse events (SAE);  
• High or low enrolment of study participants; 
• Investigators workload; 
• Number of investigational sites per project; 
• Phase of the study; 
• Time and money allocated for the site audit. 
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An audit is conducted throughout the course of a “live” study, so any problems can be 
resolved. 
 
1.3.1 Trial Master File audit 
 
Trial Master Files (TMF) consists of essential study documents. Essential documents are 
those documents that individually and collectively permit the evaluation of the conduct of 
the trial and the quality of data produced. These documents serve to demonstrate the 
compliance of the investigator, sponsor and monitor with the standards of GCP and with 
the applicable regulatory requirements. The documents are filed in duplicate i.e. at the 
investigator site/institution and sponsor office. Filing the essential documents at the 
investigator site/institution and sponsor office in a timely manner can greatly assist in the 
successful management of a trial by the investigator, sponsor or monitor (7).  
The purpose of a TMF audit is to ensure that the study team and investigator have 
maintained all study information according to the protocol and SOPs and in compliance 
with requirements, guideline and regulations at the office and at the investigator site(6).  
 
The following essential study documentation is reviewed during the TMF audits to 
determine compliance with ICH GCP (6), SAGCP (8) and 21CFR parts 50, 54, 56 and 
312(9)  
• Curriculum vitae (CV) of study personnel to determine qualification and training. 
• Signature sheet/responsibility list to verify the delegation of responsibilities. 
• Regulatory notification and approval documentation. 
• Institutional Review Board (IRB) / Independent Ethics Committee (IEC) 
submission, notification, acknowledgment and approval documentation. 
• Patient Information and Consent Form review of the template consent and 
subsequent translations or amendments following IRB/IEC review. 
• Control, storage, and distribution of investigational product by reviewing all drug 
dispensing records, drug accountability records, Certificates of Analysis and drug 
disposition forms.  
• Adverse event reporting. 
• Protocol compliance through review of site visit reports, source data verification 
(SDV) documentation, the protocol deviation log and any relevant 
correspondence. 
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• Biologic specimen/special test management and handling. 
• Case history record keeping. 
• Performance of sponsor/CRO responsibilities, including review of visit reports, 
monitoring frequency and comparison with contractual obligations. 
• Retention of essential documents. 
 
The audit may be conducted in conjunction with a planned investigational site audit or 
separately. If not conducted with a scheduled site audit, the selection of the TMFs to be 
audited at the office, can be randomly based on any of the following: concerns raised by 
the monitor or other responsible individuals; Pivotal data – data upon which an 
application is based; un-audited monitor; significant findings noted during previous 
audits; funds available; logistical concerns(5). 
 
1.3.2 Investigational Site Audit 
 
In keeping with the general principals of GCP, clinical trial auditor and/or company 
should have written SOPs specifying how site audits will be conducted, how selection of 
sites will be made, and what format will be used for audit reports(4). 
 
After the selection of a particular investigator site for an audit, the auditor shall notify the 
monitor that an audit will be performed at a selected investigational site. The monitor 
shall contact the site to inform the principal investigator (PI) or study site coordinator of 
the audit and schedule proposed audit dates with the investigator (11). 
 
An investigational site audit (ISA) is usually preceded by an in-house audit of the TMF. 
The audit process might be as follows (3). 
 
 
Opening Meeting 
An auditor will interview the study team to establish: 
• Organization of the study site, and responsibilities delegated by the PI 
• Procedures and practices followed when conducting the clinical trial 
• Monitor interaction with the clinical investigational team 
• Handling of data and Case Record Form (CRF) completion 
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• Patient population, recruitment and consent procedures 
• IRB/IEC procedures 
• Investigational product (IP) storage, dispensing and accountability 
• Facilities performing laboratory testing 
 
 Following the opening meeting, the auditor shall perform the following activities, as 
appropriate to the objectives of the audit, in order to determine site compliance with 
applicable regulations, GCP, relevant SOPs and the protocol as warranted: 
 
Tour of the Facilities 
• Inspect study-related examination, testing and treatment facilities and equipment, 
including applicable maintenance and calibration records. 
• Inspect investigational product storage and preparation areas, including security 
provisions and environmental controls.  
• Inspect specimen processing and storage areas, if applicable, including relevant 
processing records and refrigerator/freezer logs.  
• Inspect record storage areas.  
 
Review all Informed Consent Forms 
• Examine in detail the informed consent documents for participants to ensure: 
¾ Compliance with ICH GCP(6), SAGCP(8) and 21CFR parts 50, 54, 56 and 
312(9):  
¾ Correct approved version was used 
¾ Informed consent forms were properly executed 
¾ Signed consents were obtained from participants prior to undergoing any 
protocol required procedures.  
 
Review the Participant Files (inclusive of source notes) and Case Record Forms (CRFs) 
• Collect a representative sample (at least three randomized participants) of CRFs 
and review against source documents;  
• Verify key safety and efficacy data experience i.e.  
¾ serious adverse events,  
¾ participants withdrawing due to adverse events,  
¾ participants recruited at different times during the recruitment period,  
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¾ participants from different referring sites.  
• Determine eligibility of participants 
¾ data on the condition of subject at the time the subject entered into the 
clinical study 
¾ data of exposure of the subject to the test article  
¾ data on the condition of the subject throughout participation in the 
investigations 
• Determine whether the investigator reported all dropouts, lost to follow-up etc 
 
Review the Investigator Site File (ISF) 
The review includes: 
• Local regulatory correspondence/approvals 
• IRB/IEC correspondence/approvals (inclusive of submissions and approvals) to 
and from the IRB/IEC and the investigator e.g.: 
¾ Protocol and amendments 
¾ Informed consent 
¾ Advertisement for subject recruitment (if applicable) 
¾ Periodic reports 
• Signed agreement between involved parties 
• CVs/qualifications to ensure properly trained and qualified 
• Delegation of responsibilities list 
• Adverse events experiences and unanticipated problems involving risk to human 
participants  
• Randomization list, enrolment log, Serious Adverse Events (SAE) reported by the 
site,  
• Laboratory normal/reference ranges 
• Records pertaining to laboratory specimen 
• Monitoring trip reports 
• Documentation of follow up to non compliances reported in trip reports 
• Electronic records/Electronic signature compliance, if applicable. 
• Subject enrolment, drop-outs, lost to follow-up, etc 
• Study correspondence (e.g., follow up letters to monitoring visits) 
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Determine if any significant discrepancies exist between this file and Trial Master File 
through comparison of ISF findings with TMF findings. 
 
Investigational Product (IP) accountability 
• Determine whether the dispenser/person that administered the test article was 
qualified and authorized (Act 101, 1965) (10), (11) 
• Determine accountability procedure for the IP (10), (11) 
• Inspect the storage area  
¾ IP stored as specified 
¾ Controlled access to the controlled substance 
• Inspect IP return and destruction procedures 
 
Record retention 
• Determine who maintains custody of the required records 
 
Electronic Records and Signature (if applicable) 
• Determine compliance with 21 CFR part 11.  
 
Review of facilities and equipment 
• Equipment validation / calibration 
• Equipment maintenance 
• Physical security 
 
Debriefing Meeting 
• At the end of the site audit, the auditor will meet with the responsible personnel to 
summarize audit findings and to resolve any misunderstandings or outstanding 
questions4. 
 
1.4 Rating of Audit Findings 
 
After an audit was conducted, the auditor usually reviews all findings to determine which 
are to be reported as non-compliance and/or quality system deficiencies. The auditor(s) 
ensures that these are documented in a clear, concise manner in an audit report (13).  
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All findings need to be supported by objective evidence and should be identified with 
reference to specific requirements of the standard(s) or other related documents against 
which the audit was conducted (13).  
 
The following approach should be considered when rating findings (13):  
• Identify procedures/activities/documents that are key to the quality of the process 
to be audited; 
• Define a set of quality requirements for each of these activities or items. For  
example: list of all documents required in a particular file, dosing compliance, core 
protocol requirements, completed informed consent forms, accuracy of data 
recording. 
• Rate each finding in relation to the defined requirements. Depending on company 
practice, these findings are sometimes rated according to the severity of the 
finding: as critical, major and minor findings. Or rank by score as best, median and 
worst. 
 
1.5 Audit Report 
 
The content of the audit report should reflect the execution of the audit. It must be dated 
and signed by the auditors and contain the following items, as applicable (13): 
• The scope, and objective of the audit; 
• The audit methodology (procedures, activities), the identification of audit team 
members and auditee representatives, audit dates, identification of the specific 
organisation audited and adherence to the audit plan; 
• Identification of the reference documents against which the audit was conducted; 
• Observations/findings  
¾ Documented clear, concise manner 
¾ Supported by objective evidence  
¾ Be identified with reference to specific requirements of the standard(s) 
against which the audit was conducted 
¾ Categorized within audit categories 
¾ Rated according to a severity scale 
• Recommendations for corrective and/or preventative actions may be included 
• Audit report distribution list 
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1.6 Rationale of the Study 
 
When performing an audit in a clinical trial numerous audit findings could be identified 
that could impact adversely on the trial. Similar findings that occur frequently could be 
considered a trend.  
Adverse findings may affect the validity, integrity, reproducibility or the safety of 
individual patients and regulatory acceptance of the study.  
 
This research project is intended to highlight re-occurring or similar audit findings which 
are associated with specific indications/diagnosis within CNS studies. Literature review 
resulted in limited references which could be an indication that minimal research were 
performed on this topic previously, this strengthens the need for further research in this 
area. 
 
Since patient safety, compliance to regulatory requirements, ICH guidelines, company 
policies and cost saving is a requirement for most pharmaceutical companies when 
conducting clinical trials the outcome of this study will serve three purposes for study 
planners.  
• It will highlight the frequency of specific audit findings, which would enable study 
planners to implement preventative measures in future trials; 
• Clinical Trial Management could use the guide to determine the level of training 
and specific GCP categories to be emphasized; 
• Building preventative procedures and/or activities into the study conduct would 
save time and money and minimize GCP non-compliance.  
 
1.7 Aims and Objectives 
 
The primary purpose of this study will be to:  
• Analyze the categories and severity of audit findings identified in audits conducted 
on CNS Trials per CNS indication; 
• Establish whether there is an association between the CNS indications that have 
been audited, the category of the audit finding and the severity of the audit finding; 
• Perform a trend analysis to identify the re-occurrence of similar audit findings in 
CNS studies.  
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CHAPTER 2 
2.0 METHODOLOGY 
2.1 Data Collection Methodology 
 
A total of 123 CNS audit reports were obtained from retrospective audits conducted by the 
Quality Assurance Departments of Quintiles in South Africa and Europe between the year 
2002 and 2005. These include 105 investigator site audits and 18 trial master file audits.  
It was decided to make use of audit reports from the same therapeutic area i.e. Central 
Nervous System in order to ensure that the complexity of the audits would be the similar. 
 
Audits reports were selected from South Africa and Europe because:  
• the same QA audit procedures, criteria and similar set of Standard Operating 
Procedures (SOPs) were used by Quintiles in SA and Europe from 2000; 
• the same QA SMART database is used in SA as in Europe, therefore, there are 
similar categories for classification of audit findings. 
 
2.1.1 Exclusion Criteria 
 
• Findings from audits conducted by the QA Departments outside the above-
mentioned world region i.e. Australia, America and India will not be included in 
the research project since the database differs from Quintiles SA and Europe; 
• Minor audit findings will not be evaluated since the access to the findings is 
limited; 
• Other therapeutic clinical trials will be excluded; 
• Other type of audits i.e. System audits, Data Management audits and Clinical 
Research Organization audits will be excluded; 
• Trial data generated before 2000 will not be included in this research project since 
different QA audit procedures, criteria and SOPs were used by Quintiles in SA and 
Europe before the year 2000. 
 
Due to a general confidentiality agreement between the client and Quintiles, the name of 
the client or the name of the drugs investigated, will not be revealed in this report. 
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2.2 Data Analysis 
 
Initially, the audit findings recorded in the audit reports were consolidated and analyzed 
according to a three-fold system of categorization. Findings were categorized in terms of 
the: 
• CNS indication that has been audited (refer to section 2.2.1); 
• Audit categories according to SMART Database (refer to section 2.2.2); 
• Severity as critical or major (refer to section 2.2.3). 
 
The data was analyzed using the software package STATA version 8. Statistical 
calculations included descriptive statistics using frequencies and percentages. As an 
example the percentage of major and critical GCP non-compliance findings were 
categorized, calculated and recorded. Furthermore, the process examined the degree of 
dependence or association between some of the variables in the data using contingency 
table analysis.  
 
The contingency table was analyzed by means of a chi-square analysis. In this study the 
chi-squared test was applied on: the relationships between the audit category and severity 
rating for findings per indication – examined if severity is dependent or associated with 
category or not for each indication. 
Throughout the analysis a significance level of 5% will be used. 
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2.2.1 CNS Indications 
 
Indications in which findings were presented have been listed below.  
• Alzheimer’s Disease 
• Bipolar Disorder 
• Cervical Dystonia 
• Epilepsy 
• Generalised Anxiety Disorder 
• Major Depressive Disorder 
• Migraine 
• Multiple Sclerosis 
• Panic Disorder 
• Parkinson’s 
• Post-herpetic-neuralagia 
• Schizophrenia 
• Social Phobia 
• Spasticity 
• Traumatic Brain Injury 
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2.2.2 Audit Categories 
 
Audit findings recorded in the audit reports were categorized in the following 74 
categories as per the QA SMART Database.  
• Analysis 
• Backup and Recovery 
• Clinical Investigator's Brochure 
• Clinical Management Plan 
• Code break Envelopes 
• Coding 
• Computer Hardware 
• Computer Software 
• Computer System Change Control 
• Computer System Functional Design 
• Computer System Module Testing 
• Computer System Physical Design 
• Computer System Requirements Specification 
• Computer System Source Code 
• Computer System Test 
• Confidentiality 
• Consent 
• Contract 
• CRF Completion 
• Computer System Validation 
• Data Edits 
• Data Entry Instructions 
• Data Handling 
• Data Management Plan 
• Data Queries 
• Database 
• Database Access 
• Database Change Control 
• Database Validation 
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• Disaster Recovery 
• Equipment 
• Essential Documents 
• Ethics Committee 
• Facilities 
• Investigational Product 
• Investigator Responsibilities 
• IT Handbook 
• Laboratory 
• Laboratory/Biological Samples 
• Manual Data Edits 
• Monitoring 
• Monitoring Management 
• No critical or major issues identified 
• Procedures and Work Instructions 
• Programming Standards 
• Project Hand-over 
• Project Organisation /Communication 
• Protocol and Amendments 
• Protocol Violations 
• Quality Assurance 
• Quality Control 
• Quality Management 
• Range and Logic checks 
• Records Management 
• Recruitment and Randomization 
• Regulatory 
• Report Content 
• Resources 
• Risk Management 
• Safety Reporting 
• Security 
• Source Data 
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• Staff 
• Statistical Analysis Plan 
• Study Design 
• Study Documentation 
• Sub-contractor Management 
• Suppliers 
• Support 
• Tracking of Project Status 
• Training 
• Unassigned 
• User Acceptance Testing 
• Year 2000 
 
2.2.3 Finding Rating as Critical or Major  
 
The severity of audit findings that has been rated as critical or major according to the 
following Quintiles Quality assurance SOP 15 rating criteria: 
 
Findings rated as critical: 
• Threaten scientific, ethical, regulatory or business integrity and could invalidate 
the acceptability of a study (or part of it) to a sponsor or regulatory body, or 
invoke regulatory action; 
• Seriously challenge the integrity of key efficacy assessment methodology at one or 
more sites in a study (e.g. gross failure to control the way assessments are 
performed, no documentation of procedure, inadequate training in performing key 
assessments, no calibration or quality control checks); 
• Seriously challenge the reliability of key efficacy data at one or more sites in a 
study (e.g. no supporting source data where expected); 
• Represent a serious, systematic failure to observe appropriate patient rights (e.g. 
failure to seek appropriate ethical approval for the study, failure to obtain consent, 
failure to inform patients of critical safety issues, failure to inform patients of tests 
undertaken or abuse of patient data); 
• Represent a systematic failure in the reporting of critical safety data to the patients, 
regulatory authorities and/or ethics committees across the study. 
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• Seriously challenge the viability/accountability of the investigational product at 
one or more sites in the study. 
• Requires immediate and prompt action 
 
Examples of findings rated as critical include: 
• The comparator product had been dispensed to the study patients from marketed 
stock, not intended for clinical trial usage; 
• The investigator backdated/altered the date of patient signatures on consent forms; 
• Ethics committee approval had not been obtained for the Protocol, yet the study 
had been conducted at the site.  
 
Findings rated as major: 
• Have an impact upon scientific, ethical, regulatory or business integrity and which, 
if left unattended could become critical; 
• Have the potential to escalate into a critical finding as described above; 
• Be systematic, or of a magnitude that challenges the integrity of data or 
methodology applied across multiple patients at a site; 
• Represent a significant non-compliance with ICH-GCP, applicable regulatory 
requirements - including Data Protection requirements, or corporate Standard 
Operating Procedures; 
• Increase the safety risk to subjects; 
• Requires timely action. 
 
Examples include: 
• Investigational Product (IP) dosing regime, as described in the protocol, was not 
correctly followed; 
• Informed consent not dated by a subject;  
• Protocol amendments/revised consent forms had not been submitted to the Ethics 
Committee for approval. 
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Minor findings: 
• Indicate a potential systematic fault in process, which could lead to major or 
critical findings if, repeated or escalated 
 
Examples include: 
• Discrepancies were identified between the actual number of tablets returned and 
the number of IP tablets recorded on the IP Accountability Log; 
• The investigator dated the informed consent form on behalf of a few subjects in 
the study; 
• Submission and approval documentation did not contain adequate information to 
determine which version of the informed consent was approved. 
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CHAPTER 3 
3.0 RESULTS 
3.1 Audit Reports Analysis  
 
A total of 123 audit reports from Europe and South Africa were obtained which resulted 
in the assessment of 15 Central Nervous System (CNS) Indications. A total of 106 Audit 
reports were obtained from Europe and 17 audit reports from South Africa.  
 
Table 3.1 summarized the type of audit conducted and reports obtained per region per 
indication.  
 
Table 3.1 List of type of audit reports per region per indication 
Europe South Africa Indication 
*ISA **TMF *ISA **TMF 
Total 
Alzheimer’s Disease 1  1  2 
Bipolar Disorder 2 3   5 
Cervical Dystonia 1    1 
Epilepsy 6  1 1 8 
GAD 18  1 1 20 
MDD 10 1 5 2 18 
Migraine 2 3   5 
Multiple Sclerosis 2 1   3 
Panic Disorder 8  1  9 
Parkinson’s  4 1  1 6 
PHND 2    2 
Schizophrenia 10 1  1 12 
Social Phobia 18  1 1 20 
Spasticity 1    1 
Traumatic Brain Injury 10 1   11 
Total 95 11 10 7 123 
*ISA: Investigational Site Audit          **TMF: Trial Master File Audit 
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A total of 506 audit findings were derived from the 123 audit reports. A total of 458 audit 
findings related to investigational site audits reports i.e. 407 (91.47%)) audit findings from 
Europe and 51 (83.61 %) from South Africa. A total of 48 (9.49%) audit findings were 
identified from trial master file audits performed in Europe (38 (8.54%)) and South Africa 
(10 (16.39%)).  
 
Table 3.2 indicates the number of audit findings obtained per type of audit per region. 
 
Table 3.2 Percentage and frequency of audit findings per type of audit per region 
Region 
Type of Audit Europe South 
Africa 
Total 
Investigational Site  407 51 458 
% 91.46 83.61 90.51 
Trial Master File  38 10 48 
% 8.54 16.39 9.49 
Total  445 61 506 
 100.00 100.00 100.00 
 
From the 123 audit reports a total of 506 audit findings were reported for the 15 
indications that were assessed.  
 
Table 3.3 reflects the frequency and percentage of audit findings obtained per region per 
indication.  
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Table 3.3 Frequency and percentage of audit findings per indication per region 
Indication Europe South Africa Total 
Alzheimer's Disease  3 0 3 
% 0.67 0.00 0.59 
Bipolar Disorder  8 0 8 
% 1.80 0.00 1.58 
Cervical Dystonia  6 0 6 
% 1.35 0.00 1.19 
Epilepsy  20 3 23 
% 4.49 4.92 4.55 
GAD 39 2 41 
% 8.76 3.28 8.10 
MDD 58 45 103 
% 13.03 73.77 20.36 
Migraine  22 0 22 
% 4.94 0.00 4.35 
 Multiple Sclerosis  31 0 31 
% 6.97 0.00 6.13 
 Panic Disorder 33 0 33 
% 7.42 0.00 6.52 
Parkinson's Disease  10 0 10 
% 2.25 0.00 1.98 
PHND 10 0 10 
% 2.25 0.00 1.98 
Schizophrenia  45 5 50 
% 10.11 8.20 9.88 
Social Phobia  127 6 133 
% 28.54 9.84 26.28 
Spasticity  3 0 3 
% 0.67 0.00 0.59 
Traumatic Brain Injury 30 0 30 
% 6.74 0.00 5.93 
 Total  445 61 506 
 100.00 100.00 100.00 
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3.2 Severity Analysis 
 
Table 3.4 summarizes the total percentage of the 506 audit findings, which were rated as 
major or critical, within the CNS Therapeutic area. Refer to Appendix A (page 47) for a 
detail rating analysis of audit finding as categorized per indication. 
 
Table 3.4 Severity ratings per indication  
Severity 
Major Critical Total Indication 
Freq. % Freq. % Freq. % 
Alzheimer’s Disease 3 0.64% 0 0.00% 3 0.59% 
Bipolar Disorder 8 1.69% 0 0.00% 8 1.58% 
Cervical Dystonia 6 1.27% 0 0.00% 6 1.19% 
Epilepsy 19 4.03% 4 11.76% 23 4.55% 
GAD 41 8.69% 0 0.00% 41 8.10% 
MDD 95 20.13% 8 23.53% 103 20.36% 
Migraine 18 3.81% 4 11.76% 22 4.35% 
Multiple Sclerosis 29 6.14% 2 5.88% 31 6.13% 
Panic Disorder 33 6.99% 0 0.00% 33 6.52% 
Parkinson’s 10 2.12% 0 0.00% 10 1.98% 
PHND 10 2.12% 0 0.00% 10 1.98% 
Schizophrenia 37 7.84% 13 38.24% 50 9.88% 
Social Phobia  131 27.75% 2 5.88% 133 26.28% 
Spasticity 3 0.64% 0 0.00% 3 0.59% 
Traumatic Brain Injury 29 6.14% 1 2.94% 30 5.93% 
Total 472 100.00% 34 100.00% 506 100.00% 
 
Table 3.5 -3.11 summarize the indications with audit findings rated as major and critical 
within a specific category.  
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Table 3.5  Severity analysis per audit category for Epilepsy 
Severity Category 
Major Critical 
Total 
 Code break Envelopes  1 0 1 
 % 5.26 0.00 4.35 
 Consent  2 1 3 
 % 10.53 25.00 13.04 
IP 3 1 4 
 % 15.79 25.00 17.39 
Investigator Responsibility 3 0 3 
 % 15.79 0.00 13.04 
Laboratory/Biological 
Samples 
1 0 1 
 % 5.26 0.00 4.35 
 Monitoring  1 0 1 
 % 5.26 0.00 4.35 
Monitoring Management  1 0 1 
 % 5.26 0.00 4.35 
 Protocol Violations  1 0 1 
 % 5.26 0.00 4.35 
Protocol and Amendments  1 1 2 
 % 5.26 25.00 8.70 
 Safety Reporting  2 1 3 
 % 10.53 25.00 13.04 
 Source Data  1 0 1 
 % 5.26 0.00 4.35 
 Study Documentation  1 0 1 
 % 5.26 0.00 4.35 
Training  1 0 1 
 % 5.26 0.00 4.35 
 Total  19 4 23 
  100.00 100.00 100.00 
Bold: Highest percentage results per category 
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Table 3.6  Severity analysis per audit category for Major Depressive Disorder 
Severity Category 
Major Critical 
Total 
 CRF Completion  4 0 4 
 % 4.21 0.00 3.88 
Clinical Management Plan  1 0 1 
 % 1.05 0.00 0.97 
 Code break Envelopes  1 0 1 
 % 1.05 0.00 0.97 
Confidentiality  1 0 1 
 % 1.05 0.00 0.97 
 Consent  7 0 7 
 % 7.37 0.00 6.80 
Contract  2 0 2 
 % 2.11 0.00 1.94 
 Ethics Committee  10 0 10 
 % 10.53 0.00 9.71 
IP 6 1 7 
 % 6.32 12.50 6.80 
Investigator Responsibility 5 0 5 
 % 5.26 0.00 4.85 
Laboratory/Biological 
Samples 
5 1 6 
 % 5.26 12.50 5.83 
Monitoring  7 3 10 
 % 7.37 37.50 9.71 
Monitoring Management  5 0 5 
 % 5.26 0.00 4.85 
Procedures/Work Instruction  1 1 2 
 % 1.05 12.50 1.94 
Protocol Violations 4 0 4 
 % 4.21 0.00 3.88 
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Table 3.6  Severity analysis per audit category for Major Depressive Disorder 
Severity Category 
Major Critical 
Total 
Protocol and Amendment  2 0 2 
 % 2.11 0.00 1.94 
 Quality Assurance  1 0 1 
 % 1.05 0.00 0.97 
Records Management  1 0 1 
 % 1.05 0.00 0.97 
 Regulatory  1 0 1 
 % 1.05 0.00 0.97 
 Source Data  14 1 15 
 % 14.74 12.50 14.56 
 Study Documentation  12 1 13 
 % 12.63 12.50 12.62 
 Safety Reporting  4 0 4 
 % 4.21 0.00 3.88 
Training  1 0 1 
 % 1.05 0.00 0.97 
 Total  95 8 103 
  100.00 100.00 100.00 
Bold: Highest percentage results per category 
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Table 3.7 Severity analysis per audit category for Migraine 
Severity Category  
Major Critical 
Total 
 Consent  0 1 1 
 % 0.00 25.00 4.55 
Contract  3 0 3 
 % 16.67 0.00 13.64 
 Ethics Committee  0 2 2 
 % 0.00 50.00 9.09 
Investigational Product 1 0 1 
 % 5.56 0.00 4.55 
 Monitoring  1 1 2 
 % 5.56 25.00 9.09 
Procedures/Work Instruction  1 0 1 
 % 5.56 0.00 4.55 
 Protocol Violations  5 0 5 
 % 27.78 0.00 22.73 
Records Management  2 0 2 
 % 11.11 0.00 9.09 
 Source Data  2 0 2 
 % 11.11 0.00 9.09 
 Study Documentation  2 0 2 
 % 11.11 0.00 9.09 
Training  1 0 1 
 % 5.56 0.00 4.55 
 Total  18 4 22 
  100.00 100.00 100.00 
Bold: Highest percentage results per category 
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Table 3.8  Severity analysis per audit category for Multiple Sclerosis 
Severity Category  
Major Critical 
Total 
 CRF Completion  1 0 1 
 % 3.45 0.00 3.23 
 Consent  5 0 5 
 % 17.24 0.00 16.13 
IP  5 1 6 
 % 17.24 50.00 19.35 
Investigator Responsibility 1 0 1 
 % 3.45 0.00 3.23 
 Monitoring  2 0 2 
 % 6.90 0.00 6.45 
Monitoring Management  1 0 1 
 % 3.45 0.00 3.23 
Records Management  1 0 1 
 % 3.45 0.00 3.23 
 Regulatory  2 0 2 
 % 6.90 0.00 6.45 
 Safety Reporting  4 0 4 
 % 13.79 0.00 12.90 
 Source Data  1 1 2 
 % 3.45 50.00 6.45 
 Study Documentation  6 0 6 
 % 20.69 0.00 19.35 
 Total  29 2 31 
  100.00 100.00 100.00 
Bold: Highest percentage results per category 
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Table 3.9  Severity analysis per audit category for Schizophrenia 
Severity Category  
Major Critical 
Total 
Clinical Management P  2 0 2 
 % 5.41 0.00 4.00 
 Code break Envelopes  1 0 1 
 % 2.70 0.00 2.00 
 Consent  2 1 3 
 % 5.41 7.69 6.00 
 Ethics Committee  2 1 3 
 % 5.41 7.69 6.00 
IP  4 4 8 
 % 10.81 30.77 16.00 
Investigator Responsibility 4 2 6 
 % 10.81 15.38 12.00 
 Monitoring  3 1 4 
 % 8.11 7.69 8.00 
Monitoring Management  1 0 1 
 % 2.70 0.00 2.00 
Procedures/Work Instruction  1 0 1 
 % 2.70 0.00 2.00 
 Protocol Violations  4 0 4 
 % 10.81 0.00 8.00 
Protocol and Amendment 1 0 1 
 % 2.70 0.00 2.00 
Quality Management  0 1 1 
 % 0.00 7.69 2.00 
 Regulatory  1 0 1 
 % 2.70 0.00 2.00 
Resources  1 0 1 
 % 2.70 0.00 2.00 
 Safety Reporting  2 0 2 
 % 5.41 0.00 4.00 
Bold: Highest percentage results per category 
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Table 3.9  Severity analysis per audit category for Schizophrenia 
Severity Category  
Major Critical 
Total 
 Source Data  2 3 5 
 % 5.41 23.08 10.00 
 Study Documentation  4 0 4 
 % 10.81 0.00 8.00 
Training  2 0 2 
 % 5.41 0.00 4.00 
 Total  37 13 50 
  100.00 100.00 100.00 
Bold: Highest percentage results per category 
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Table 3.10  Severity analysis per audit category for Social Phobia 
Severity Category  
Major Critical 
Total 
 CRF Completion  2 0 2 
 % 1.53 0.00 1.50 
 Consent  11 0 11 
 % 8.40 0.00 8.27 
Contract  1 0 1 
 % 0.76 0.00 0.75 
 Essential Documents  1 0 1 
 % 0.76 0.00 0.75 
 Ethics Committee  4 0 4 
 % 3.05 0.00 3.01 
Investigational Product 18 0 18 
 % 13.74 0.00 13.53 
Investigator Responsibility 3 0 3 
 % 2.29 0.00 2.26 
Laboratory/Biological 
Samples 
6 0 6 
 % 4.58 0.00 4.51 
 Monitoring  7 1 8 
 % 5.34 50.00 6.02 
Monitoring Management  3 0 3 
 % 2.29 0.00 2.26 
Procedures/Work 
Instructions 
1 0 1 
 % 0.76 0.00 0.75 
 Protocol Violations  24 0 24 
 % 18.32 0.00 18.05 
Protocol and Amendment 3 0 3 
 % 2.29 0.00 2.26 
Records Management  1 0 1 
 % 0.76 0.00 0.75 
Recruitment/Randomization 2 0 2 
 % 1.53 0.00 1.50 
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Table 3.10  Severity analysis per audit category for Social Phobia 
Severity Category  
Major Critical 
Total 
 Safety Reporting  2 0 2 
 % 1.53 0.00 1.50 
 Source Data  30 1 31 
 % 22.90 50.00 23.31 
 Study Documentation  12 0 12 
 % 9.16 0.00 9.02 
 Total  131 2 133 
  100.00 100.00 100.00 
Bold: Highest percentage results per category 
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Table 3.11 Severity analysis per audit category for Traumatic Brain Injury 
Severity Category  
Major Critical 
 Total 
 CRF Completion  1 0 1  
 % 3.45 0.00 3.33  
CSV  1 0 1  
 % 3.45 0.00 3.33  
 Consent  5 1 6  
 % 17.24 100.00  20.00  
Contract  1 0 1  
 % 3.45 0.00 3.33  
IP 3 0 3  
 % 10.34 0.00  10.00  
Laboratory/Biological 
Samples 
4 0 4  
 % 13.79 0.00  13.33  
 Monitoring  1 0 1  
 % 3.45 0.00 3.33  
Records Management  1 0 1  
 % 3.45 0.00 3.33  
Recruitment/Randomization  1 0 1  
 % 3.45 0.00 3.33  
 Safety Reporting  5 0 5  
 % 17.24 0.00  16.67  
 Source Data  3 0 3  
 % 10.34 0.00  10.00  
 Study Documentation  2 0 2  
 % 6.90 0.00 6.67  
Training  1 0 1  
 % 3.45 0.00 3.33  
 Total  29 1  30  
  100.00 100.00  100.00  
Bold: Highest percentage results per category 
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Figure 3.1 includes a bar chart of the information listed in table 3.4 (page 20) to serve as a 
graphic representation of the difference in the percentage of audit findings rated as major 
or critical for each indication.  
 
Figure 3.1 Severity of audit findings within the CNS Therapeutic Area 
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Figure 3.2 and figure 3.3 serve as graphic representations of the percentage audit findings 
rated as major or critical for each indication per region.  
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Figure 3.2 Indications by Severity for Europe 
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Figure 3.3 Indications by Severity for South Africa 
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3.3 Trend Analysis 
 
Table 3.12 highlights the frequency and percentage of audit findings within an audit 
category. Refer to Appendix B (page 68) for a detail listing of re-occurring audit findings 
as categorized. 
 
Table 3.12 Frequency and percentage of audit findings per category 
Category Frequency Percentage Cumulative 
Analysis  1 0.20 0.20 
 CSV  1 0.20 0.40 
 Case Record Form 
Completion  
12 2.37 2.77 
 Clinical Management Plan  4 0.79 3.56 
Codebreak Envelopes  5 0.99 4.55 
 Confidentiality  1 0.20 4.74 
 Consent  46 9.09 13.83 
Contract  9 1.78 15.61 
Essential Documents  1 0.20 15.81 
 Ethics Committee  28 5.53 21.34 
 Facilities  2 0.40 21.74 
Investigational Product  64 12.65 34.39 
Investigator Responsibilities  24 4.74 39.13 
Laboratory/Biological 
Samples  
20 3.95 43.08 
 Monitoring  37 7.31 50.40 
 Monitoring Management  12 2.37 52.77 
Procedures and Work 
Instructions  
7 1.38 54.15 
Protocol Violations  41 8.10 62.25 
Protocol and Amendments  10 1.98 64.23 
Quality Assurance  1 0.20 64.43 
Quality Management  1 0.20 64.62 
Records Management  6 1.19 65.81 
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Table 3.12 Frequency and percentage of audit findings per category 
Category Frequency Percentage Cumulative 
Recruitment and 
Randomization  
3 0.59 66.40 
Regulatory  4 0.79 67.19 
Resources  1 0.20 67.39 
Safety Reporting  24 4.74 72.13 
Source Data  85 16.80 88.93 
Study Documentation  48 9.49 98.42 
Training  7 1.38 99.80 
Unassigned  1 0.20 67.39 
Total  506 100.00  
Bold: Highest percentage results per category 
 
Table 3.13 highlights the frequency and percentage of the 506 audit findings within a 
category per region. 
 
Table 3.13   Frequency and percentage of audit findings per category per region 
Region 
Category 
Europe South Africa 
Total 
Analysis  1 0 1 
 % 0.22 0.00 0.20 
CSV  1 0 1 
 % 0.22 0.00 0.20 
Case Record Form   11 1 12 
 % 2.47 1.64 2.37 
Clinical Management Plan  3 1 4 
 % 0.67 1.64 0.79 
 Code break Envelopes  4 1 5 
 % 0.90 1.64 0.99 
Confidentiality  0 1 1 
 % 0.00 1.64 0.20 
 Consent  41 5 46 
 % 9.21 8.20 9.09 
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Table 3.13   Frequency and percentage of audit findings per category per region 
Region 
Category 
Europe South Africa 
Total 
Contract  9 0 9 
 % 2.02 0.00 1.78 
 Essential Documents  1 0 1 
 % 0.22 0.00 0.20 
 Ethics Committee  24 4 28 
 % 5.39 6.56 5.53 
 Facilities  2 0 2 
 % 0.45 0.00 0.40 
IP 56 8 64 
 % 12.58 13.11 12.65 
Investigator Responsibility  21 3 24 
 % 4.72 4.92 4.74 
Laboratory/Biological Samples 17 3 20 
 % 3.82 4.92 3.95 
 Monitoring  37 0 37 
 % 8.31 0.00 7.31 
Monitoring Management  10 2 12 
 % 2.25 3.28 2.37 
Procedure/Work Instruction  6 1 7 
 % 1.35 1.64 1.38 
 Protocol Violations  38 3 41 
 % 8.54 4.92 8.10 
Protocol and Amendment  8 2 10 
 % 1.80 3.28 1.98 
 Quality Assurance  0 1 1 
 % 0.00 1.64 0.20 
Quality Management  1 0 1 
 % 0.22 0.00 0.20 
Records Management  4 2 6 
 % 0.90 3.28 1.19 
Recruitment / Randomization  3 0 3 
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Table 3.13   Frequency and percentage of audit findings per category per region 
Region 
Category 
Europe South Africa 
Total 
 % 0.67 0.00 0.59 
 Regulatory  3 1 4 
 % 0.67 1.64 0.79 
Resources  0 1 1 
 % 0.00 1.64 0.20 
 Safety Reporting  20 4 24 
 % 4.49 6.56 4.74 
 Source Data  76 9 85 
 % 17.08 14.75 16.80 
 Study Documentation  41 7 48 
 % 9.21 11.48 9.49 
Training  6 1 7 
 % 1.35 1.64 1.38 
 Unassigned  1 0 1 
 % 0.22 0.00 0.20 
 Total  445 61 506 
  100.00 100.00 100.00 
 Bold: Highest percentage results per category 
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3.4  Testing Association  
 
Table 3.14 reflects the evaluation to identify associations between the audit category and 
severity rating for findings obtained from Europe considering each indication 
 
Table 3.14 Testing association per indication for Europe 
Indication Pearson  
Chi-
squares 
Degrees of 
Freedom  
Probability Conclusion
Alzheimer’s 
Disease 
*NA - - - 
Bipolar Disorder *NA - - - 
Cervical 
Dystonia 
*NA - - -  
Epilepsy 8.541 12 0.741 Not 
significant 
GAD *NA - - - 
MDD 24.997 16 0.070 Not 
significant 
Migraine 18.638 10 0.045 Significant 
Multiple 
Sclerosis 
8.908 10 0.541 Not 
Significant 
Panic Disorder *NA - - - 
Parkinson’s *NA - - - 
PHND *NA - - - 
Schizophrenia 13.602 15 0.556 Not 
significant 
Social Phobia  8.183 16 0.943 Not 
significant 
Spasticity *NA - - - 
Traumatic Brain 
Injury 
4.138 12 0.981 Not 
significant 
*Not applicable (NA): Only one category (Major) was available and test could not be 
performed. 
 
Hypothesis: The null hypothesis being tested is that there is no association between 
category and severity for the indication under consideration.  
For Migraine; the results showed significance which implies that there is association 
between the category and severity. For the other indications, there was no evidence to 
show that severity is dependent on category of indications.  
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Table 3.15 reflects the evaluation if the audit category is associated with severity for data 
obtained from South Africa considering each Indication 
 
Table 3.15 Testing association per indication for South Africa 
Indication Pearson  
Chi-
squares 
Degrees of 
Freedom  
Probability Conclusion
Epilepsy *NA - - - 
GAD *NA - - - 
MDD 18.08 18 0.450 Not 
significant 
Schizophrenia *NA - - - 
Social Phobia  *NA - - - 
*Not applicable (NA): Only one category (Major) was available and test could not be 
performed. 
 
Testing associations could not be performed for the following indications in South Africa 
since no audits were performed: Bipolar Disorder, Cervical Dystonia, Migraine, Multiple 
Sclerosis, Post-herpetic-neuralgia, Spasticity, and Traumatic Brain Injury. Refer to table 
3.1 (List of type of audit reports per region per indication, 17). 
 
Hypothesis: The null hypothesis being tested is that there is no association between 
category and severity for the indication under consideration.  
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CHAPTER 4 
4.0 DISCUSSION AND CONCLUSIONS 
4.1  Audit Results 
 
It is evident from the table 3.3 (Frequency and percentage of audit findings per region; 
page 20) that the most prominent indication with highest percentage of findings is Social 
Phobia which accounts for 26.3%. This indication also has the highest percentage of audit 
findings in Europe i.e. 28. 5%. The second highest amount of audit findings related to 
Major Depressive Disorder that accounts for 20.4%. This indication accounts for the 
highest amount of audit findings in South Africa i.e. 73.8 %. The lowest is Spasticity and 
Alzheimer’s disease which accounts for 0.6% each respectively.  
 
Table 3.4 (Severity ratings per indication; page 21) shows that eight (8) of the fifteen (15) 
indications investigated have audit findings rated as critical and major. This is Epilepsy, 
Major Depressive Disorder, Migraine, Multiple Sclerosis, Schizophrenia, Social Phobia 
and Traumatic Brain Injury. The highest frequency of critical findings was for 
Schizophrenia i.e. thirteen (38.2%). Second highest was for Major Depressive Disorder 
i.e. eight (23.5%) critical audit findings. Refer to Appendix A (Audit finding analysis per 
indication, page 48) for a complete listing of severity rating of individual audit findings 
per indication. Social Phobia had the highest percentage (27.8%) of major audit findings. 
The second highest percentage (20.1%) of major audit findings was once again for Major 
Depressive Disorder. 
 
From the fifteen (15) Central Nervous System (CNS) indications investigated only eight 
indications were audited in South Africa i.e. Alzheimer’s Disease, Epilepsy, Generalized 
Anxiety Disorder, Major Depressive Disorder, Panic Disorder, Parkinson’s, 
Schizophrenia, Social Phobia (table 3.1, Summary of type of audit reports obtained per 
region per indication, page 18). It is interesting to note that no major or critical audit 
findings were identified for Alzheimer, Panic Disorder and Parkinson’s disease as 
opposed to data obtained from Europe. Refer to table 3.3 (Frequency and percentage of 
audit findings per indication per region, page 20) and figure 3.3. (Indication by severity 
for South Africa, page 33). 
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4.2 Re-occurring Audit Findings per Category 
 
From the 74 audit categories as per SMART database (page 13), 506 audit findings were 
categorized into 29 audit categories (Table 3.12; Frequency and percentage of audit 
findings per category; page 34). No audit findings were identified for the remainder of the 
45 non-compliance categories. The reason for this might be that audit findings relating to 
these categories would be applicable to different type of audits i.e. data management 
audits, system audits, not included in this analysis as reflected in table 3.2 (Percentage and 
frequency of audit findings per type of audit per region; page 19).   
 
From table 3.13 (Frequency and percentage of audit findings per category per region; page 
35); no audit findings were identified within the following categories for South Africa i.e. 
contracts, essential documents, facilities, monitoring, quality management, recruitment 
and randomization. 
 
It is clear from table 3.12 (frequency and percentage of audit findings per category, page 
34) the highest frequency of audit findings i.e. eighty-five (85) was reported for 
deficiencies noted in the non-compliance category relating to source data (16.80%). The 
second most prevalent audit findings related to Investigational Product (12.65%).  The 
audit category, study documentation reflects the third most audit findings (9.49%). Forty-
six audit findings were identified in the non-compliance category consent (9.09%). The 
level of results is similar for South Africa and Europe (Table 3.13; Frequency and 
percentage of audit findings per category per region; page 35). The percentage of protocol 
violations in Europe (8.54%) is twice the percentage identified in South Africa (4.92%). 
This category represents fifth highest result level for both Europe and South Africa.  
 
Re-occurring audit findings per category are listed in Appendix B (page 68). 
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4.2.1 Source Data 
 
Questionable source data # could have a critical effect on the authentic reporting of data to 
the sponsor. Unreliable source data cannot substantiate the integrity of the trial data that 
have been collected and submitted to regulatory authorities for approval of an 
Investigational Product. Insufficient source data result in protocol violations and protocol 
non-compliance. This was confirmed through further analysis of the frequency and type of 
audit findings in the non-compliance category of protocol violations which represents the 
fifth category with most audit findings (41 audit findings).  
 
The majority of audit findings were from this section. Most of the audit findings related to 
information that was missing in the source data (20), source data not appropriately 
recorded (12) or updated retrospectively (12). Further findings identified related to 
changes to source data that cannot be substantiate (6), source data missing at site (6) and 
instance where the monitor was not able to verify critical data within source 
documentation (equal frequency of 6).  
 
It might be argued that the high frequency of source data audit findings relates to short 
medical notes written by Psychiatrists and medical doctors specifically within the 
therapeutic area. In a majority of instances the participants symptoms, emotions, activity 
level and sleep disorders are completed directly onto evaluation checklist and rating scales 
such as Likert Pain Scale, Patient's Global Impression of Change in Pain (PGIC), SF-36 
Health Survey Quality of Life Questionnaire, Work Productivity and Activity Impairment 
(WPAI) Questionnaire. These become the only source data available. Consequently, data 
captured in the CRF, eligibility criteria and protocol compliance could not always be 
confirmed. This resulted in audit findings such as missing information, inappropriate 
recording of source data; or difficulty to verify critical data within source documentation. 
 
                                            
# All information in original records and certified copies of original records of clinical 
findings, observations, or other activities in a clinical trial necessary for the reconstruction 
and evaluation of the trial. Source data are contained in source documents (original 
records or certified copies). 
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Inter-individual rating differences occur in instances when different Investigators 
(psychiatrist) assess a trial subject. Thus, related to changes to source data that cannot be 
confirmed. Differences between raters can critically influence study outcomes and should 
therefore be eliminated before the commencement of the study conduct.  
 
Capturing of insufficient source data could also be a result of poor monitoring (which 
represents the sixth category with most audit findings (37 audit findings)), ignorance from 
study team, lack of investigator involvement and insufficient training. 
 
Prior to a clinical trial study planners should clarify and explain in a monitoring manual 
the expected source data that is required from medical notes. This might ensure that 
accurate data is derived from medical notes and reported in Case Records Forms.  
The monitor should discuss and highlight as early as the initiation visit, the type of 
information expected to be recorded in the source documents. The monitor should take 
into account the investigator’s procedure of documenting medical procedures and clarify 
what type of information is routinely recorded at this visit. This could result in pre-
identifying medical notes of inferior quality immediately. The monitor could then explain 
what additional information is required in order to complete the Case Report Form and 
adhere to protocol requirements. Instances when investigator insists on direct data entry 
into the CRF a site specific standard operating procedure should be compiled and 
submitted for approval to clinical management team. If approved it should be provided to 
auditors during an audit to prevent unsubstantiated findings. Essential source data entries 
as defined by local regulatory should however be enforced.    
 
4.2.2 Investigational Product (IP) 
 
The second most audit findings (64) 12,65% were derived from deficiencies identified in 
this audit category relating to IP. The majority of findings were no/inadequate 
documentation of IP receipt at site and IP Inventory Record not maintained up to date 
(equal frequency of 11). The second most audit findings related to no/inadequate 
documentation of IP dispensing to patients and IP dosing regime not followed (equal 
frequency of 8). The latter resulting in protocol violations, which reflected eight audit 
findings relating to non-compliance with the dosing schedule. 
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Further findings related to inadequate IP storage facilities for (4). Discrepancies in data 
between IP accountability log and other study documentation such as CRF (3). 
 
New legislation regarding the dispensing of medication became effective during 2003. 
Investigators are not allowed to compound or dispense medicine unless he or she is the 
holder of a license as contemplated in subsection (1) (a) and (section 22 C) of Medicines 
and Related Substances Act, 1965 (Act No. 101 Of 1965) as amended16 and Regulations 
made in terms of the Act (Section 18)10.  
Since 2004/2005 investigators are obligate to obtain an additional dispensing license if IP 
should be dispense form practice or sub-contract this function to a register pharmacy. 
Thus, greater attention will be given, at various sites, to maintain accurate records of IP 
receipt, handling, dispensing and retrieval. 
 
Study planners and monitors should put quality control procedures in place to ensure 
Investigational Product compliance. This must be implemented from study initiation. An 
investigational site that does not comply with regulation should not be considered.  
Continuous education by study team during site initiation and thereafter should be 
implemented to ensure accurate IP storage, access control and dispensing.  
 
4.2.3 Study Documentation 
 
Findings in the audit category of study documentation were third most prevalent. Fourteen 
of the audit findings related to inadequate control of study documentation. Other findings 
in the category related to; translations of key documents, e.g. unavailability of regulatory 
approval, ethics approval, local language consents forms (8) in the TMF and/or ISF. Six 
findings related to incomplete study documentation. Delegation of significant trial-related 
activities not documented (5). Key regulatory submission and approvals were difficult to 
find. The master patient log did not contain adequate details for identifying the patients 
(3), and the screening log was not available at the site or had not been completed (3). 
 
These findings could once again be the result of poor monitoring. Monitor’s lack of 
knowledge and experience regarding study documentation requirements and company’s 
standard operating procedures (SOPs) should be considered. Line manager and study 
planners should ensure that the study team has proper knowledge and understanding of 
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SOPs requirements. Proper training should address these concerns. This might lead to 
better understanding of requirements and accurate implementation of the SOPs. Not only 
should study documentation be identified from study start, but content requirements 
should be verified and emphasized. 
 
4.2.4 Consent 
 
The audit category reflected fourth most prevalent frequency (46 (9.09%)). Consent 
findings identified in the category could adversely impact the study’s ethical and 
regulatory integrity and the integrity of patients’ participations. This in effect could 
invalidate the acceptability of patient data or study data in whole.  
 
Consent process not completed prior to study procedures commencing (13) occurred most 
frequently in this category. This finding was a major for the following indications: 
Generalized Anxiety Disorder (2), Major Depressive Disorder (1), Migraine (1), Multiple 
Sclerosis (1), Panic Disorder (1), Post Herpgic Neuralgia Disorder (2), Social Phobia (2), 
Traumatic Brain Injury (1). It was rated as critical for Migraine. 
 
The second most frequent findings related to patients that had not received copies of the 
Patient Informed Consent (7). Other significant findings in this audit category included 
inappropriate consent process procedures (5), informed consent not dated by the subjects 
(5). The incorrect version of the informed consent used (3) or no signed informed consent 
available for subjects (3). 
 
Not only is the consent process vital to any clinical study, but emphasis should be placed 
on the consent process in this particular research field.  
 
To be able to improve the quality of a patients life and to ensure patient safety are crucial 
aspects of clinical trials. Monitoring of investigational product management should be 
performed with be monitored. Study planners should ensure that investigators are well-
conversant with the consent process. Monitors should know that the review and 
continuous review of participant consent forms are one of the first monitoring functions to 
be performed at any investigational site.  
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As required by ICH GCP6, SA GCP8, 21 CFR part 519 and OHRP –Office of Human 
Research Protection17 the informed consent clearly state that the monitor(s), the auditor(s), 
the IRB/IEC, and the regulatory authority(ies) will be granted direct access∗ to the 
subject's original medical records for verification of clinical trial procedures and/or data, 
without violating the confidentiality of the subject. By signing a written informed consent 
form, the subject or the subject's legally acceptable representative is authorizing such 
access.  
Thus, if no consent is present or consent process was questionable we cannot access 
patient’s source data or use data.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
                                            
∗ Direct Access 
Permission to examine, analyzes, verify, and reproduce any records and reports that are 
important to evaluation of a clinical trial. Any party (e.g., domestic and foreign regulatory 
authorities, sponsor's monitors and auditors) with direct access should take all reasonable 
precautions within the constraints of the applicable regulatory requirement(s) to maintain 
the confidentiality of subjects' identities and sponsor’s proprietary information. 
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CHAPTER 5 
5.0 RECOMMENDATION AND CONCLUSIONS  
5.1 Recommendation 
 
The results of this investigation suggested a need for substantial improvement in three 
important areas. Firstly adherence to the study requirements inclusive of relevant Standard 
Operating Procedures (SOPs). Secondly the development of better defined protocols and 
thirdly training of monitors.  
 
It is vital that the importance of protocol adherence is made clear. Site staff should be 
aware of the implications of protocol deviations. Monitors should be trained to be vigilant. 
Areas of inadequacy identified during monitoring should be highlighted without delay 
during a site visit. 
 
Study planners can play a proactive role to reduce the audit findings. Site staff should be 
educated regarding study conduct expectations. Monitors with experience in this research 
field should be involved in the study.  
 
The key to a successful trial is the protocol. The protocol should be well written. It is 
imperative that this is not adapted from the equivalent adult trial and should be written or 
reviewed by personnel with experience of trials within the specific indication.  
 
Specific attention should be given to the indication under investigation, source data 
requirements, the informed consent process, study documentation and the procedure 
regarding IP management.  
 
It is recommended that these results be taken into consideration. Non-compliance with 
SOPs and regulations are costly to the sponsor and CRO, serving only to delay the drug 
development process. This is an outcome that is detrimental to both the patient and 
industry at large. 
 
The small sample may not be representative of the wider picture- however the results are 
somewhat alarming. 
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APPENDIX A: AUDIT FINDING ANALYSIS PER INDICATION 
Severity Frequency  Category Finding 
Alzheimer’s Disease 
Major 1 Ethics Committee SAEs and annual reports were not provided to the ethics committee 
Major 2 Source Data Source data missing at site. 
Total 3   
Bipolar Disorder 
Major 1 Ethics Committee 
No documentary evidence that 
protocol amendment(s), or revised 
ICF, was submitted/notified to the EC
Major 1 Facilities Inadequate Fire Protection where the study is conducted 
Major 1 Investigational Product Certificates of Analysis not available for all batches of medication used. 
Major 1 Laboratory/Biological Samples  
Inadequate quality control 
procedures. 
Major 1 Protocol and Amendments 
Superseded version of the protocol in 
use at the site 
Major 1 Safety Reporting No evidence of SAE being reported appropriately 
Major 1 Source Data Concerns with the reliability of the source data 
Major 1 Study Documentation Study documentation not adequately controlled 
Total 8   
Cervical Dystonia 
Major 1 Ethics Committee No EC approval for the satellite site. 
Major 2 Ethics Committee SAEs and annual reports were not provided to the ethics committee 
Major 1 Monitoring No initiation visit reports on site. 
Major 1 Monitoring Non-compliance with monitoring SOPs 
Major 1 Study Documentation 
Master patient log did not contain 
adequate details to identify the 
patients 
Total 6   
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APPENDIX A: AUDIT FINDING ANALYSIS PER INDICATION 
Severity Frequency  Category Finding 
Epilepsy 
Major 1 Codebreak Envelopes Inadequate tracking/confirmation of receipt 
Major 2 Consent Consent and Information Sheet do not contain adequate information 
Critical 1 Consent Consent process not conducted appropriately 
Major 1 Investigational Product Certificates of Analysis not available for all batches of medication used. 
Critical 1 Investigational Product 
Discrepancies in data between IP 
accountability log and other study 
documentation e.g. CRF 
Major 2 Investigational Product No/inadequate documentation of receipt at site 
Major 3 Investigator Responsibilities 
Inadequate control of the study by the 
Principal Investigator. 
Major 1 Laboratory/Biological Samples  
Laboratory samples not handled as 
detailed in the protocol 
Major 1 Monitoring Inadequate follow up of an issue 
Major 1 Monitoring Management 
Deficiencies in 
strategy/documentation of 
accompanied visits 
Critical 2 Protocol and Amendments 
Study procedure(s) not described in 
the protocol 
Major 1 Protocol Violations Multiple protocol violations. 
Critical 1 Safety Reporting Adverse events not reported on the CRF. 
Major 2 Safety Reporting No evidence of SAE being reported appropriately 
Major 1 Source Data Inconsistencies between CRFs and source  
Major 1 Study Documentation 
No translations of key documents e.g. 
regulatory and ethics approvals, local 
language consent forms etc. available.  
Major 1 Training Inadequate strategy for training new staff 
Total 23   
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APPENDIX A: AUDIT FINDING ANALYSIS PER INDICATION 
Severity Frequency  Category Finding 
Generalised Anxiety Disorder 
Major 1 Codebreak Envelopes Accidental discarding of the disclosure  
Major 2 Consent Consent process not completed prior to study procedures commencing 
Major 1 Consent Copy of consent form not provided to subject 
Major 1 Consent Incorrect version of the consent form in use 
Major 1 Consent Informed consent not dated by the patient. 
Major 1 Consent No signed consent form available 
Major 1 Consent Patients not signed new information made available during the trial 
Major 1 Contract Non-compliance with contractual obligations 
Major 2 CRF Completion CRF not completed correctly 
Major 1 Facilities Inadequate space to conduct the study
Major 1 Investigational Product Inadequate storage facilities for IP 
Major 2 Investigational Product IP Inventory Record not maintained up to date 
Major 2 Investigational Product No/inadequate documentation of dispensing to patients 
Major 1 Investigational Product No/inadequate documentation of receipt at site 
Major 1 Investigational Product Re-labelling process deficient 
Major 2 Investigator Responsibilities 
Inadequate control of the study by the 
Principal Investigator 
Major 1 Monitoring Backlog in the monitoring and collection of CRFs 
Major 2 Monitoring Inadequate follow up of an issue 
Major 1 Monitoring Monitor not reviewing all source documentation available 
Major 1 Monitoring Protocol violations had not been detected by the monitor. 
Major 1 Procedures and Work Instructions 
Inadequate control/distribution of 
project instructions and/or customer 
SOPs 
                                   
 51  
APPENDIX A: AUDIT FINDING ANALYSIS PER INDICATION 
Severity Frequency  Category Finding 
Generalised Anxiety Disorder cont. 
Major 1 Protocol and Amendments Inadequate document control 
Major 1 Protocol Violations Multiple protocol violations. 
Major 1 Protocol Violations Patient not withdrawn despite meeting criteria for withdrawal 
Major 1 Source Data Concerns with the reliability of the source data 
Major 1 Source Data Contradictory information in the source documents 
Major 2 Source Data Inadequate documentation to support patient eligibility 
Major 1 Source Data Information missing in the source data 
Major 2 Source Data Source data missing at site. 
Major 1 Source Data Source data not appropriately recorded 
Major 1 Source Data Source data/patient notes updated retrospectively. 
Major 1 Training Key staff at site not trained in protocol requirements 
Major 1 Unassigned Unassigned 
Total 41   
Major Depressive Disorder 
Major 1 Clinical Management Plan Unapproved/incomplete approval 
Major 1 Codebreak Envelopes Inadequate tracking/confirmation of receipt 
Major 1 Confidentiality Client Confidentiality comprised 
Major 3 Consent Consent and Information Sheet do not contain adequate information 
Major 2 Consent Copy of consent form not provided to subject 
Major 1 Consent Incorrect version of the consent form in use 
Major 1 Consent No signed consent form available 
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APPENDIX A: AUDIT FINDING ANALYSIS PER INDICATION 
Severity Frequency  Category Finding 
Major Depressive Disorder cont. 
Major 1 Contract Missing or inadequate documentation of out-of-scope work 
Major 1 Contract Non-compliance with contractual obligation 
Major 1 CRF Completion CRF not completed correctly 
Major 3 CRF Completion CRFs signed prior to completion of CRF 
Major 3 Ethics Committee 
Documentation submitted to the 
ethics committee were not 
available/incomplete 
Major 1 Ethics Committee EC membership list not available or voting members not listed 
Major 1 Ethics Committee 
EC not compliant with ICH GCP in 
terms of membership and/or 
procedure. 
Major 1 Ethics Committee Lack of original ethics committee approval documentation 
Major 3 Ethics Committee 
No documentary evidence that 
protocol amendment(s), or revised 
Informed Consent Form, was 
submitted/notified to the ethics 
committee 
Major 1 Ethics Committee Submission documents inaccurate/incomplete 
Major 1 Investigational Product 
Discrepancies in data between IP 
accountability log and other study 
documentation e.g. CRF. 
Major 1 Investigational Product Dosing regime not followed 
Major 2 Investigational Product Inadequate storage facilities for IP 
Critical 1 Investigational Product No record of temperature monitoring of IP storage facility. 
Major 1 Investigational Product No/inadequate documentation of dispensing to patients 
Major 1 Investigational Product No/inadequate documentation of receipt at site 
Major 2 Investigator Responsibilities 
Inadequate documentation of the 
delegation of responsibilities to site 
staff. 
Major 1 Investigator Responsibilities 
Inappropriate delegation of tasks to 
inexperienced site staff. 
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APPENDIX A: AUDIT FINDING ANALYSIS PER INDICATION 
Severity Frequency  Category Finding 
Major Depressive Disorder cont. 
Major 2 Investigator Responsibilities 
Site staff were inadequately qualified 
and/or supervised.  
Major 1 Laboratory/Biological Samples  
Inadequate quality control 
procedures. 
Major 1 Laboratory/Biological Samples  
Laboratory Accreditation had 
expired. 
Major 3 Laboratory/Biological Samples  No alarm on freezer in case of failure.
Critical 1 Laboratory/Biological Samples 
Reference Ranges 
inadequate/incomplete 
Major 1 Monitoring 
Follow-up letters not being sent to the 
site despite problems having been 
identified. 
Critical 2 Monitoring Inadequate contact with Principal Investigator 
Major 1 Monitoring Monitor unfamiliar with protocol  
Major 5 Monitoring 
Monitoring visits not conducted 
according to contractual 
requirements. 
Critical 1 Monitoring 
Monitoring Visits not conducted 
according to contractual 
requirements.  
Major 5 Monitoring Management 
Inadequate support of an 
inexperienced monitor, leading to 
poor performance. 
Major 1 Procedures and Work Instructions 
Non compliance with company 
policy, procedure, work instruction or 
project instruction  
Critical 1 Procedures and Work Instructions 
Project Instructions not consistent 
with contract.  
Major 1 Protocol and Amendments 
Inadequate handling of protocol 
amendments 
Major 1 Protocol and Amendments 
Protocol, or relevant protocol 
amendments(s), was not on file 
Major 1 Protocol Violation  Inadequate communication of protocol violation 
Major 2 Protocol Violations Multiple protocol violations. 
Major 1 Protocol Violations  Multiple tests/assessments for one or more patients were not performed 
Major 1 Quality Assurance Audit follow-up inadequate 
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APPENDIX A: AUDIT FINDING ANALYSIS PER INDICATION 
Severity Frequency  Category Finding 
Major Depressive Disorder cont. 
Major 1 Records Management 
Many documents have inadequate 
identification or document control 
features. 
Major 1 Regulatory Relevant regulatory approval documentation not on file  
Major 1 Safety Reporting Documentation of SAE inadequate 
Major 1 Safety Reporting No evidence of SAE being reported appropriately 
Major 2 Safety Reporting SAEs not reported within an appropriate timeframe. 
Major 2 Source Data Changes to source data not recorded appropriately 
Major 1 Source Data Concerns with the reliability of the source data 
Major 2 Source Data Inadequate documentation to support patient eligibility 
Critical 1 Source Data Information missing in the source data 
Major 3 Source Data Information missing in the source data 
Major 1 Source Data Lack of control on source data received from third parties 
Major 5 Source Data Unable to verify critical data within source documentation 
Major 5 Study Documentation Delegation of responsibilities list did not include all trial related activities. 
Major 1 Study Documentation 
Key regulatory documents e.g. 
submissions and approvals not easy 
to locate. 
Major 3 Study Documentation 
No translations of key documents e.g. 
regulatory and EC approvals, local 
language consent forms etc. available.
Major 2 Study Documentation Screening log not available  
Major 1 Study Documentation Study documentation incomplete 
Critical 1 Study Documentation Study files poorly organized 
Major 1 Training Staff training records incomplete 
Total 103   
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Migraine 
Critical 1 Consent Consent process not completed prior to study procedures commencing 
Major 2 Contract Letter of Intent has expired 
Major 1 Contract Missing or inadequate documentation of out-of-scope work 
Critical 2 Ethics Committee SAEs and annual reports were not provided to the ethics committee 
Major 1 Investigational Product No/inadequate documentation of receipt at site 
Critical 1 Monitoring 
Monitoring visits not conducted 
according to contractual 
requirements. 
Major 1 Monitoring Site selection deficiencies 
Major 1 Procedures and Work Instructions 
Appropriate procedures, work 
instructions or project instructions are 
not in place 
Major 2 Protocol Violations Multiple tests/assessments for one or more patients were not performed 
Major 2 Protocol Violations Patient not withdrawn despite meeting criteria for withdrawal 
Major 1 Protocol Violations 
Tests relevant to the 
inclusion/exclusion criteria not being 
reviewed prior to randomization 
Major 2 Records Management 
Many documents have inadequate 
identification or document control 
features 
Major 1 Source Data Information missing in the source data 
Major 1 Source Data Source data not appropriately recorded 
Major 2 Study Documentation 
Master patient log did not contain 
adequate details to identify the 
patients 
Major 1 Training Staff training records incomplete 
Total 22   
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Multiple Sclerosis 
Major 1 Consent Consent process not completed prior to study procedures commencing 
Major 1 Consent Copy of consent form not provided to subject 
Major 1 Consent Incorrect version of the consent form in use 
Major 1 Consent Informed consent not dated by the patient. 
Major 1 Consent Patients not signed new information made available during the trial 
Major 1 CRF Completion CRF not completed correctly 
Major 1 Investigational Product Import documentation was not available. 
Critical 1 Investigational Product IP incorrectly prepared for administration. 
Major 1 Investigational Product No record of temperature monitoring of IP storage facility. 
Major 2 Investigational Product No/inadequate documentation of receipt at site 
Major 1 Investigational Product No/inadequate documentation of receipt at site 
Major 1 Investigator Responsibilities  
Investigator involved in multiple 
aspects of the study, potential conflict 
of interest in the roles 
Major 1 Monitoring Monitor not reviewing all source documentation available. 
Major 1 Monitoring 
Monitoring visit reports/SDV records 
do not clearly identify the source 
documentation available 
Major 1 Monitoring Management 
Inadequate handover or inadequate 
documentation of the handover of 
investigator responsibilities at sites 
Major 1 Records Management Archive Strategy not defined or inadequate 
Major 1 Regulatory Discrepancies in the dates of submissions and approvals 
Major 1 Regulatory FDA 1572 out of date. 
Major 2 Safety Reporting 
Multiple discrepancies between 
master log of  safety reports and the 
reports either in-house or on site 
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Multiple Sclerosis 
Major 2 Safety Reporting SAEs not reported within an appropriate timeframe 
Critical 1 Source Data Source data not appropriately recorded 
Major 1 Source Data Source data not appropriately recorded 
Major 1 Study Documentation 
Key regulatory documents e.g. 
submissions & approvals not easy to 
locate. 
Major 2 Study Documentation 
No translations of key documents e.g. 
regulatory and ethics approvals, local 
language consent forms etc. available 
Major 1 Study Documentation Screening log not available/completed. 
Major 1 Study Documentation Study documentation not adequately controlled 
Major 1 Study Documentation Study files generally poorly organized 
Total 31   
Panic Disorder 
Major 1 Consent Consent process not completed prior to study procedures commencing 
Major 1 CRF Completion Final version of CRF does not comply with the protocol 
Major 1 Ethics Committee EC approval documents do not contain adequate detail 
Major 1 Investigational Product Inadequate/no instructions for IP accountability and reconciliation 
Major 3 Investigational Product IP Inventory Record not maintained up to date 
Major 1 Investigational Product No/inadequate documentation of dispensing to patients 
Major 1 Investigational Product No/inadequate documentation of receipt at site 
Major 1 Investigator Responsibilities  
Inadequate control of the study by the 
Principal Investigator 
Major 1 Investigator Responsibilities  
Inappropriate delegation of tasks to 
inexperienced site staff. 
Major 1 Investigator Responsibilities  
Lack of resource  to perform study 
appropriately 
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Panic Disorder 
Major 1 Monitoring 
Follow-up letters not being sent to the 
site despite problems having been 
identified 
Major 1 Monitoring Monitor not reviewing all source documentation available. 
Major 1 Safety Reporting Documentation of SAE inadequate 
Major 2 Safety Reporting SAEs not reported within an appropriate timeframe. 
Major 3 Source Data Changes to source data cannot be substantiated 
Major 4 Source Data Information missing in the source data 
Major 5 Source Data Source data/patient notes updated retrospectively. 
Major 4 Study Documentation Study documentation incomplete  
Total 33   
Parkinson’s 
Major 1 Codebreak Envelopes Codebreak envelopes opened without adequate written explanation 
Major 2 Ethics Committee EC approval documents do not contain adequate detail 
Major 1 Investigational Product IP expired 
Major 1 Investigator Responsibilities 
Inadequate documentation of the 
delegation of responsibilities to site 
staff. 
Major 1 Laboratory/Biological Samples  Laboratory report(s) missing. 
Major 1 Monitoring Management 
Inadequate support of an 
inexperienced monitor,  
Major 1 Source Data Source data missing at site. 
Major 1 Study Documentation 
No translations of key documents e.g. 
regulatory and ethics approvals, local 
language consent forms etc. available.
Major 1 Study Documentation Study documentation not adequately controlled 
Total 10   
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Post Herpgic Neuralgia 
Major 1 Analysis Unexplained change in analysis. 
Major 1 Clinical Management Plan Unapproved/incomplete approval 
Major 2 Consent Consent process not completed prior to study procedures commencing 
Major 1 Contract Non-compliance with contractual obligations 
Major 1 CRF Completion CRF inconsistent with source documents 
Major 1 Ethics Committee 
Written ethics committee approval for 
original protocol or significant 
protocol amendment was not on file 
Major 1 Investigational Product No/inadequate documentation of dispensing to patients 
Major 1 Laboratory/Biological Samples  
Reference ranges 
inadequate/incomplete 
Major 1 Procedures and Work Instructions 
Procedures required by regulations 
are not in place 
Total 10   
Schizophrenia 
Major 1 Clinical Management Plan Key sections missing 
Major 1 Clinical Management Plan Unapproved/incomplete approval 
Major 1 Codebreak Envelopes Accidental discarding of code break at site 
Major 1 Consent Consent and Information Sheet do not contain adequate information 
Major 1 Consent Informed consent not dated by the patient. 
Critical 1 Consent Questionable patient signatures of consent  
Major 1 Ethics Committee 
Documents submitted to the ethics 
committee were not 
available/incomplete 
Critical 1 Ethics Committee No EC approval for the satellite site. 
Major 1 Ethics Committee 
Written ethics committee approval for 
original protocol or significant 
protocol amendment was not on file 
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Schizophrenia 
Critical 1 Investigational Product 
Discrepancies in data between IP 
accountability log and other study 
documentation e.g. CRF. 
Major 1 Investigational Product Dosing regime not followed 
Major 1 Investigational Product Inadequate storage facilities for IP 
Major 1 Investigational Product Incorrect IP dispensed to patients 
Critical 1 Investigational Product 
Label did not meet requirements of 
Annex 13/local regulatory 
requirements 
Critical 2 Investigational Product No/inadequate documentation of dispensing to patients 
Major 1 Investigational Product Re-labelling process deficient 
Critical 1 Investigator Responsibilities 
Poor understanding by site staff of the 
protocol requirements 
Major 1 Investigator Responsibilities  
Inadequate control of the study by the 
Principal Investigator. 
Major 1 Investigator Responsibilities  
Inadequate documentation of the 
delegation of responsibilities to site 
staff. 
Critical 1 Investigator Responsibilities  
Site staff were inadequately qualified 
and/or supervised 
Major 2 Investigator Responsibilities  
Site staff were inadequately qualified 
and/or supervised 
Major 1 Monitoring 
Monitoring visits not conducted 
according to contractual 
requirements. 
Major 1 Monitoring Protocol violations had not been detected by the monitor 
Critical 1 Monitoring Site selection deficiencies 
Major 1 Monitoring Visit reports were not issued within the required timelines 
Major 1 Monitoring Management 
Inadequate support of an 
inexperienced monitor, leading to 
poor performance. 
Major 1 Procedures and Work Instructions 
Non compliance with company 
policy, procedure, work instruction or 
project instruction 
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Severity Frequency  Category Finding 
Schizophrenia 
Major 1 Protocol and Amendments 
Inadequate handling of protocol 
amendments 
Major 1 Protocol Violations Inadequate communication of protocol violations 
Major 1 Protocol Violations Multiple protocol violations. 
Major 1 Protocol Violations Non-compliance with the dose schedule. 
Major 1 Protocol Violations Safety data not assessed prior to administration of study drug 
Critical 1 Quality Management Inadequate management of quality issues 
Major 1 Regulatory 
Relevant regulatory 
approval/notification documentation 
not on file at the site 
Major 1 Resources Inadequate/inappropriate resource allocated 
Major 1 Safety Reporting No evidence of SAE being reported appropriately 
Major 1 Safety Reporting SAEs not reported within an appropriate timeframe. 
Critical 1 Source Data Contradictory information in the source documents 
Major 1 Source Data False or fabricated data entered. 
Critical 1 Source Data Inadequate documentation to support patient eligibility 
Major 1 Source Data Information missing in the source data 
Critical 1 Source Data Significant inconsistencies between CRF and source document 
Major 1 Study Documentation 
Key regulatory documents e.g. 
submissions & approvals not easy to 
locate. 
Major 1 Study Documentation Study documentation incomplete 
Major 1 Study Documentation Study documentation not adequately controlled 
Major 1 Study Documentation Study files generally poorly organized 
Major 1 Training Project specific training inadequate 
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Schizophrenia 
Major 1 Training Training strategy not documented or inadequately documented 
Total 50   
Social Phobia 
Major 4 Consent Consent process not completed prior to study procedures commencing 
Major 1 Consent Consent process not conducted appropriately 
Major 3 Consent Copy of consent form not provided to subject 
Major 1 Consent Inadequate version control 
Major 2 Consent Informed consent not dated by the patient. 
Major 1 Contract No finalised contract/scope of work available for the study. 
Major 1 CRF Completion CRF inconsistent with source documents 
Major 1 CRF Completion No CRF completed for screen failure subject 
Major 1 Essential Documents No insurance certificate available 
Major 1 Ethics Committee 
Documents submitted to the ethics 
committee were not 
available/incomplete 
Major 1 Ethics Committee Lack of original ethics committee approval documentation 
Major 2 Ethics Committee Protocol amendment implemented prior to EC approval 
Major 4 Investigational Product Dosing regime not followed 
Major 1 Investigational Product Inadequate/no documentation of return of IP to patients 
Major 5 Investigational Product IP Inventory Record not maintained up to date 
Major 1 Investigational Product 
Label did not meet requirements of 
Annex 13/local regulatory 
requirements 
Major 1 Investigational Product Monitor completed the IP Inventory Record. 
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Social Phobia cont 
Major 1 Investigational Product No/inadequate documentation of dispensing to patients 
Major 2 Investigational Product No/inadequate documentation of receipt at site 
Major 1 Investigational Product No/inadequate documentation of retrieval from site 
Major 2 Investigational Product Potential unblinding of study personnel 
Major 3 Investigator Responsibilities 
Inadequate control of the study by the 
Principal Investigator 
Major 2 Laboratory/Biological Samples 
Laboratory samples not handled as 
detailed in the protocol 
Major 4 Laboratory/Biological Samples Slow reporting of laboratory results 
Critical 1 Monitoring Inadequate follow up of an issue 
Major 3 Monitoring Inadequate follow up of an issue 
Major 2 Monitoring Monitor unfamiliar with protocol  
Major 1 Monitoring Non-compliance with monitoring SOPs 
Major 1 Monitoring Site selection deficiencies 
Major 1 Monitoring Management 
Deficiencies in 
strategy/documentation of 
accompanied visits 
Major 1 Monitoring Management 
Inadequate support of an 
inexperienced monitor, leading to 
poor performance 
Major 1 Monitoring Management 
Visit reports on file not signed by 
monitor and/or CTL 
Major 1 Procedures and Work Instructions 
Non compliance with company 
policy, procedure, work instruction or 
project instructions 
Major 1 Protocol and Amendments 
Amendment implemented prior to 
approval 
Major 2 Protocol and Amendments Inadequate document control 
Major 2 Protocol Violations Documentation of protocol violations/deviations not adequate. 
Major 6 Protocol Violations Multiple protocol violations. 
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Severity Frequency  Category Finding 
Social Phobia cont. 
Major 2 Protocol Violations Multiple tests/assessments for one or more patients were not performed 
Major 6 Protocol Violations Non-compliance with the dose schedule. 
Major 2 Protocol Violations Patient not withdrawn despite meeting criteria for withdrawal 
Major 2 Protocol Violations 
Patient visits not conducted within 
the time period laid out in the 
protocol 
Major 1 Protocol Violations Safety data not assessed prior to administration of study drug 
Major 3 Protocol Violations 
Tests relevant to the 
inclusion/exclusion criteria not being 
reviewed prior to randomization 
Major 1 Records Management 
Many documents have inadequate 
identification or document control 
features. 
Major 2 Recruitment and Randomisation 
Multiple issues regarding recruitment 
of patients 
Major 1 Safety Reporting Handling of safety updates/IND alert letters inadequate 
Major 1 Safety Reporting No evidence of SAE being reported appropriately 
Major 1 Source Data Computer print-outs not signed and dated 
Major 4 Source Data Concerns with the reliability of the source data 
Major 1 Source Data Inadequate documentation to support patient eligibility 
Major 8 Source Data Information missing in the source data 
Major 1 Source Data Lack of control on source data received from third parties 
Major 2 Source Data Source data missing at site. 
Critical 1 Source Data Source data not appropriately recorded 
Major 6 Source Data Source data not appropriately recorded 
Major 6 Source Data Source data/patient notes updated retrospectively. 
Major 1 Source Data Unable to verify critical data within source documentation. 
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Social Phobia cont. 
Major 1 Study Documentation Correction fluid used on study  
Major 1 Study Documentation 
No translations of key documents e.g. 
regulatory and ethics approvals, local 
language consent forms etc. available 
Major 1 Study Documentation Study documentation incomplete 
Major 8 Study Documentation Study documentation not adequately controlled 
Major 1 Study Documentation Study documentation not finalised at the appropriate time 
Total 133   
Spasticity 
Major 1 Investigational Product IP Inventory Record not maintained up to date 
Major 1 Protocol Violations Non-compliance with the dose schedule. 
Major 1 Source Data Inadequate documentation to support patient eligibility 
Total 3   
Traumatic Brain Injury 
Major 1 Consent Consent process not completed prior to study procedures commencing 
Major 1 Consent Consent process not conducted appropriately 
Major 1 Consent Consent process not conducted appropriately 
Major 1 Consent Consent process not conducted appropriately 
Major 1 Consent Inadequate version control 
Critical 1 Consent No signed consent form available 
Major 1 Contract Contract between Quintiles and Investigator not available 
Major 1 CRF Completion CRF not completed correctly 
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Traumatic Brain Injury cont. 
Major 1 CSV CSV documentation does not meet regulatory requirements 
Major 1 Investigational Product Dosing regime not followed 
Major 1 Investigational Product Dosing regime not followed 
Major 1 Investigational Product Inadequate/no documentation of return of IP from patient 
Major 1 Laboratory/Biological Samples 
Inadequate follow-up and 
documentation of out-of-range 
values. 
Major 1 Laboratory/Biological Samples  
Inadequate follow-up and 
documentation of out-of-range values 
Major 1 Laboratory/Biological Samples  
Inadequate follow-up and 
documentation of out-of-range values 
Major 1 Laboratory/Biological Samples  
Inadequate follow-up and 
documentation of out-of-range 
values. 
Major 1 Monitoring Monitor not reviewing all source documentation available. 
Major 1 Records Management 
Many documents have inadequate 
identification or document control 
features 
Major 1 Recruitment and Randomisation 
Multiple issues regarding recruitment 
of patients 
Major 1 Safety Reporting Inadequate follow-up of SAE(s) 
Major 1 Safety Reporting Inadequate follow-up of SAE(s) 
Major 1 Safety Reporting SAEs not reported within an appropriate timeframe 
Major 1 Safety Reporting SAEs not reported within an appropriate timeframe 
Major 1 Safety Reporting SAEs not reported within an appropriate timeframe. 
Major 1 Source Data Changes to source data not recorded appropriately 
Major 1 Source Data Information missing in the source data 
Major 1 Source Data Source data not appropriately recorded 
Major 1 Study Documentation Study documentation not adequately controlled 
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Traumatic Brain Injury cont 
Major 1 Study Documentation Study documentation not adequately controlled 
Major 1 Training Project specific training inadequate 
Total 30   
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  Analysis  
Major 1 Analysis Unexplained change in analysis. 
Total 1     
  Clinical Management Plan  
Major 1 Clinical Management Plan Key sections missing 
Major 3 Clinical Management Plan Unapproved/incomplete approval 
Total 4     
  Codebreak Envelopes  
Major 1 Codebreak Envelopes Accidental discarding of codebreak at site 
Major 1 Codebreak Envelopes Accidental discarding of the disclosure  
Major 1 Codebreak Envelopes Codebreak envelopes opened without adequate written explanation 
Major 2 Codebreak Envelopes Inadequate tracking/confirmation of receipt 
Total 5     
  Confidentiality  
Major 1 Confidentiality Client Confidentiality comprised 
Total 1     
  Consent  
Major 17 Consent 
Consent process not completed prior to 
study procedure commencing 
Critical 1 Consent 
Consent process not completed prior to 
study procedures commencing 
Critical 1 Consent 
Consent process not conducted 
appropriately 
Major 4 Consent 
Consent process not conducted 
appropriately 
Major 7 Consent 
Copy of consent form not provided to 
subject 
Major 2 Consent Inadequate version control 
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Severity Frequency Category Finding 
Major 3 Consent 
Incorrect version of the consent form in 
use 
Major 5 Consent 
Informed consent not dated by the 
patient. 
Critical 1 Consent No signed consent form available 
Major 2 Consent No signed consent form available 
Major 2 Consent 
Patients not signed new information 
made available during the trial 
Critical 1 Consent 
Questionable patient signatures of 
consent  
Total 46     
  Contract  
Major 1 Contract Contract between Quintiles and Investigator not available 
Major 2 Contract Letter of Intent has expired 
Major 2 Contract Missing or inadequate documentation of out-of-scope work 
Major 1 Contract No finalised contract/scope of work available for the study. 
Major 3 Contract Non-compliance with contractual obligation 
Total 9     
  CRF Completion  
Major 2 CRF Completion CRF inconsistent with source documents 
Major 5 CRF Completion CRF not completed correctly 
Major 3 CRF Completion CRFs signed prior to completion of CRF 
Major 1 CRF Completion Final version of CRF does not comply with the protocol 
Major 1 CRF Completion No CRF completed for screen failure subject 
Total 12     
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  CSV  
Major 1 CSV CSV documentation does not meet regulatory requirements 
Total 1     
  Essential Documents  
Major 1 Essential Documents No insurance certificate available 
Total 1     
      Ethics Committee   
Major 5 Ethics Committee 
Documents submitted to the ethics 
committee were not available 
/incomplete.  
Major 3 Ethics Committee EC approval documents do not contain adequate detail 
Major 1 Ethics Committee EC membership list not available or voting members not listed 
Major 1 Ethics Committee EC not compliant with ICH GCP in terms of membership and/or procedure. 
Major 2 Ethics Committee Lack of original ethics committee approval documentation 
Major 4 Ethics Committee 
No documentary evidence that protocol 
amendment(s), or revised Informed 
Consent Form, was submitted/notified to 
the ethics committee 
Critical 1 Ethics Committee No EC approval for the satellite site. 
Major 1 Ethics Committee No EC approval for the satellite site. 
Major 2 Ethics Committee Protocol amendment implemented prior to EC approval 
Critical 2 Ethics Committee SAEs and annual reports were not provided to the ethics committee 
Major 3 Ethics Committee SAEs and annual reports were not provided to the ethics committee 
Major 1 Ethics Committee Submission documents inaccurate/incomplete 
Major 2 Ethics Committee Written EC approval for original protocol or protocol amendment not filed
Total 28     
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     Facilities   
Major 1 Facilities Inadequate Fire Protection where the study is conducted 
Major 1 Facilities Inadequate space to conduct the study 
Total 2     
    Investigational Product   
Major 2 Investigational Product Certificates of Analysis not available for all batches of medication used. 
Critical 2 Investigational Product 
Discrepancies in data between IP 
accountability log and other study 
documentation e.g. CRF 
Major 1 Investigational Product 
Discrepancies in data between IP 
accountability log and other study 
documentation e.g. CRF. 
Major 8 Investigational Product Dosing regime not followed 
Major 1 Investigational Product Import documentation was not available. 
Major 4 Investigational Product Inadequate storage facilities for IP 
Major 2 Investigational Product Inadequate/no documentation of return of IP from patient 
Major 1 Investigational Product Inadequate/no instructions for IP accountability and reconciliation 
Major 1 Investigational Product Incorrect IP dispensed to patients 
Major 1 Investigational Product IP expired 
Critical 1 Investigational Product IP incorrectly prepared for administration. 
Major 11 Investigational Product IP Inventory Record not maintained up to date 
Critical 1 Investigational Product Label did not meet requirements of Annex 13/local regulatory requirements 
Major 1 Investigational Product Label did not meet requirements of Annex 13/local regulatory requirements 
Major 1 Investigational Product Monitor completed the IP Inventory Record. 
Critical 1 Investigational Product No record of temperature monitoring of IP storage facility. 
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Major 1 Investigational Product No record of temperature monitoring of IP storage facility. 
Critical 2 Investigational Product No/inadequate documentation of dispensing to patients 
Major 6 Investigational Product No/inadequate documentation of dispensing to patients 
Major 11 Investigational Product No/inadequate documentation of receipt at site 
Major 1 Investigational Product No/inadequate documentation of retrieval from site 
Major 2 Investigational Product Potential unblinding of study personnel 
Major 2 Investigational Product Re-labelling process deficient 
Total 64     
  Investigator Responsibilities  
Major 8 Investigator Responsibilities 
Inadequate control of the study by the 
Principal Investigator. 
Major 2 Investigator Responsibilities 
Inadequate documentation of the 
delegation of responsibilities to site staff.
Major 1 Investigator Responsibilities 
Inappropriate delegation of tasks to 
inexperienced site staff. 
Critical 1 Investigator Responsibilities 
Poor understanding by site staff of the 
protocol requirements 
Major 1 Investigator Responsibilities 
Site staff were inadequately qualified 
and/or supervised.  
Major 2 Investigator Responsibilities  
Inadequate control of the study by the 
Principal Investigator 
Major 2 Investigator Responsibilities  
Inadequate documentation of the 
delegation of responsibilities to site staff.
Major 1 Investigator Responsibilities  
Inappropriate delegation of tasks to 
inexperienced site staff. 
Major 1 Investigator Responsibilities  
Investigator involved in multiple aspects 
of the study, potential conflict of interest 
in the roles 
Major 1 Investigator Responsibilities  
Lack of resource  to perform study 
appropriately 
Critical 1 Investigator Responsibilities  
Site staff were inadequately qualified 
and/or supervised 
Major 3 Investigator Responsibilities  
Site staff were inadequately qualified 
and/or supervised 
Total 24     
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  Laboratory/Biological Samples  
Major 4 Laboratory/Biological Samples 
Inadequate follow-up and documentation 
of out-of-range values. 
Major 2 Laboratory/Biological Samples 
Laboratory samples not handled as 
detailed in the protocol 
Major 4 Laboratory/Biological Samples Slow reporting of laboratory results 
Major 2 Laboratory/Biological Samples  Inadequate quality control procedures. 
Major 1 Laboratory/Biological Samples  Laboratory Accreditation had expired. 
Major 1 Laboratory/Biological Samples  Laboratory report(s) missing. 
Major 1 Laboratory/Biological Samples  
Laboratory samples not handled as 
detailed in the protocol 
Major 3 Laboratory/Biological Samples  No alarm on freezer in case of failure. 
Major 1 Laboratory/Biological Samples  Reference ranges inadequate/incomplete 
Critical 1 Laboratory/Biological Samples Reference ranges inadequate/incomplete 
Total 20     
  Monitoring  
Major 1 Monitoring 
Backlog in the monitoring and collection 
of CRFs 
Major 2 Monitoring 
Follow-up letters not being sent to the 
site despite problems having been 
identified 
Critical 2 Monitoring 
Inadequate contact with Principal 
Investigator 
Critical 1 Monitoring Inadequate follow up of an issue 
Major 6 Monitoring Inadequate follow up of an issue 
Major 4 Monitoring 
Monitor not reviewing all source 
documentation available 
Major 3 Monitoring Monitor unfamiliar with protocol  
Major 1 Monitoring 
Monitoring visit reports/SDV records do 
not clearly identify the source 
documentation available 
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Critical 2 Monitoring 
Monitoring visits not conducted 
according to contractual requirements. 
Major 6 Monitoring 
Monitoring visits not conducted 
according to contractual requirements. 
Major 1 Monitoring No initiation visit reports on site. 
Major 2 Monitoring Non-compliance with monitoring SOPs 
Major 2 Monitoring 
Protocol violations had not been detected 
by the monitor 
Critical 1 Monitoring Site selection deficiencies 
Major 2 Monitoring Site selection deficiencies 
Major 1 Monitoring 
Visit reports were not issued within the 
required timelines 
  37     
  Monitoring Management  
Major 2 Monitoring Management Deficiencies in strategy/documentation of accompanied visits 
Major 1 Monitoring Management 
Inadequate handover or inadequate 
documentation of the handover of 
investigator responsibilities at sites 
Major 8 Monitoring Management Inadequate support of an inexperienced monitor, leading to poor performance. 
Major 1 Monitoring Management Visit reports on file not signed by monitor and/or CTL 
Total 12     
  Procedures and Work Instructions  
Major 1 Procedures and Work Instructions 
Appropriate procedures, work 
instructions or project instructions are 
not in place 
Major 1 Procedures and Work Instructions 
Inadequate control/distribution of project 
instructions and/or customer SOPs 
Major 3 Procedures and Work Instructions 
Non compliance with company policy, 
SOP, work instruction or project 
instructions 
Major 1 Procedures and Work Instructions 
Procedures required by regulations are 
not in place 
Critical 1 Procedures and Work Instructions 
Project Instructions not consistent with 
contract.  
Total 7     
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  Protocol and Amendments  
Major 1 Protocol and Amendments Amendment implemented prior to approval 
Major 3 Protocol and Amendments Inadequate document control 
Major 2 Protocol and Amendments Inadequate handling of protocol amendments 
Major 1 Protocol and Amendments Protocol, or amendments(s), not on file 
Critical 1 Protocol and Amendments Study procedure(s) not described in the protocol 
Major 1 Protocol and Amendments Study procedure(s) not described in the protocol 
Major 1 Protocol and Amendments Superseded version of the protocol in use at the site 
Total 10     
  Protocol Violations  
Major 2 Protocol Violations Documentation of protocol violations/deviations not adequate. 
Major 2 Protocol Violations Inadequate communication of protocol violations 
Major 11 Protocol Violations Multiple protocol violations. 
Major 5 Protocol Violations Multiple tests/assessments for one or more patients were not performed 
Major 8 Protocol Violations Non-compliance with the dose schedule. 
Major 5 Protocol Violations Patient not withdrawn despite meeting criteria for withdrawal 
Major 2 Protocol Violations Patient visits not conducted within the time period laid out in the protocol 
Major 2 Protocol Violations Safety data not assessed prior to administration of study drug 
Major 4 Protocol Violations Inclusion/exclusion tests not being reviewed prior to randomisation 
Total 41     
  Quality Assurance  
Major 1 Quality Assurance Audit follow-up inadequate 
Total 1     
                                   
 76  
APPENDIX B: Re-OCCURING AUDIT FINDINGS PER CATEGORY 
Severity Frequency Category Finding 
  Quality Management  
Critical 1 Quality Management Inadequate management of quality issues
Total 1     
  Records Management  
Major 1 Records Management Archive Strategy not defined or inadequate 
Major 5 Records Management 
Many documents have inadequate 
identification or document control 
features. 
Total 6     
  Recruitment and Randomisation  
Major 3 Recruitment and Randomisation 
Multiple issues regarding recruitment of 
patients 
Total 3     
  Regulatory  
Major 1 Regulatory Discrepancies in the dates of submissions and approvals 
Major 1 Regulatory FDA 1572 out of date. 
Major 2 Regulatory Relevant regulatory approval documentation not on file  
Total 4     
  Resources  
Major 1 Resources Inadequate/inappropriate resource allocated 
Total 1     
  Safety Reporting  
Critical 1 Safety Reporting Adverse events not reported on the CRF. 
Major 2 Safety Reporting Documentation of SAE inadequate 
Major 1 Safety Reporting Handling of safety updates/IND alert letters inadequate 
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Major 2 Safety Reporting Inadequate follow-up of SAE(s) 
Major 2 Safety Reporting 
Multiple discrepancies between master 
log of  safety reports and the reports 
either in-house or on site 
Major 6 Safety Reporting No evidence of SAE being reported appropriately 
Major 10 Safety Reporting SAEs not reported within the appropriate timeframe. 
Total 24     
  Source Data  
Major 6 Source Data Changes to source data not recorded appropriately 
Critical 1 Source Data Contradictory information in the source documents 
Major 9 Source Data Contradictory information in the source documents 
Major 1 Source Data False or fabricated data entered. 
Critical 1 Source Data Inadequate documentation to support patient eligibility 
Major 6 Source Data Inadequate documentation to support patient eligibility 
Major 1 Source Data Inconsistencies between CRFs and source  
Critical 1 Source Data Information missing in the source data 
Major 19 Source Data Information missing in the source data 
Major 2 Source Data Lack of control on source data received from third parties 
Critical 1 Source Data Significant inconsistencies between CRF and source document 
Major 7 Source Data Source data missing at site. 
Critical 2 Source Data Source data not appropriately recorded 
Major 10 Source Data Source data not appropriately recorded 
Major 12 Source Data Source data updated retrospectively. 
Major 6 Source Data Unable to verify critical source data  
Total 85     
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Severity Frequency Category Finding 
  Study Documentation  
Major 1 Study Documentation Correction fluid used on study  
Major 5 Study Documentation 
Delegation of responsibilities list did not 
include all significant trial related 
activities. 
Major 3 Study Documentation 
Key regulatory documents e.g. 
submissions and approvals not easy to 
locate. 
Major 3 Study Documentation Master patient log did not contain adequate details to identify the patients 
Major 8 Study Documentation 
No translations of key documents e.g. 
regulatory and ethics approvals, local 
language consent forms etc. available.   
Major 3 Study Documentation Screening log not available/completed. 
Major 7 Study Documentation Study documentation incomplete  
Major 14 Study Documentation Study documentation not adequately controlled 
Major 1 Study Documentation Study documentation not finalised at the appropriate time 
Major 2 Study Documentation Study files generally poorly organized 
Critical 1 Study Documentation Study files generally poorly organized 
Total 48     
  Training  
Major 1 Training Inadequate strategy for training new staff
Major 1 Training Key staff at site not trained in protocol requirements 
Major 2 Training Project specific training inadequate 
Major 2 Training Staff training records incomplete 
Major 1 Training Training strategy not documented or inadequately documented 
Total 7     
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Severity Frequency Category Finding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Unassigned  
Major 1 Unassigned Unassigned 
Total 1     
Total 506     
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